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O1.01
PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EX-
PRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)
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Schwartz3, Lu Tian4, Holbrook Edwin Kohrt1, Joel W. Neal1, Robert 
West3, Heather A. Wakelee1  
1Stanford University School Of Medicine, Department Of Medicine, 
Division Of Oncology, Palo Alto/UNITED STATES OF AMERICA, 2Uni-
versity Of California Davis School Of Medicine, Department Of 
Internal Medicine, Division Of Hematology/Oncology, Sacramento/
UNITED STATES OF AMERICA, 3Stanford University School Of Medi-
cine, Department Of Pathology, Palo Alto/UNITED STATES OF AMER-
ICA, 4Stanford University School Of Medicine, Department Of Health 
And Research Policy, Palo Alto/UNITED STATES OF AMERICA
Background: Thymic epithelial tumors (TETs) are rare and include 
thymomas and thymic carcinomas. TETs contain lymphocytic in-
filtrates, and as they arise from an immune organ confer a unique 
tumor microenvironment. Tumor expression of the immune check-
point ligand, PD-L1, is a known mechanism for immune evasion. 
Here, we evaluated TET expression of PD-L1. 
Methods: A TMA was constructed from 69 TETs and 17 thymic 
controls (C) (including 9 paired normal thymuses adjacent to tu-
mor), at Stanford University. Each TET and C was represented by 
triplicate cores in the TMA. The pathologist (E.J.S.) was blinded 
to clinical data and sample identity. The TMA was stained with a 
monoclonal antibody (clone 15, Sino Biological) to human PD-L1 
using human placenta for staining titration. To distinguish PD-L1 
expression on epithelial cells from that on lymphocytes, a CK5/6 
cytokeratin stain was used. An intensity scale of 0, 1, 2, and 3 
representing no, equivocal, weak, and intermediate-strong staining, 
respectively, was used. Since both TETs and Cs stained for PD-L1 
at least to some degree, TETs and Cs were classified as “PD-L1 
high” if all representative cores in the TMA stained 3 on epithelial 
cells, while the remaining which did not fit this criteria were classi-
fied as “PD-L1 low.” A nonparametric permutation test was used to 
compare the PD-L1 intensity on epithelial cells between TETs and 
Cs and the Fisher’s exact test was used to correlate PD-L1 staining 
with WHO histology. A two-sided p-value ≤0.05 was considered 
statistically significant.
Results: Characteristics for 69 patients: 36M/33F; mean age 54 
years (2-86); WHO histology: 8 A, 17 AB, 14 B1, 18 B2, 7 B3, 4 C. 
PD-L1 high scores were significantly more frequent in TETs than 
Cs (68.1% vs. 17.6%, respectively, p=0.004). Majority of PD-L1 
staining was found on epithelial cells and present in > 50% of these 
cells. PD-L1 staining was both membranous and cytoplasmic. 
Only 14.8% (n=8/54) of TETs had PD-L1 staining of an associated 
lymphocytic infiltrate. There was also a significant correlation of 
PD-L1 and histology, with more aggressive histologies containing 
a higher percentage of PD-L1 high scores: B3>B2>C>B1>AB>A 
(p=0.035). In an unadjusted analysis, PD-L1 high versus PD-L1 low 
TETs demonstrated no difference in recurrence-free survival (RFS; 
p=0.2) and overall survival (OS; p=0.83). However, when adjusted 
for age and gender, PD-L1 high TETs had a worse OS (HR 5.40, 
95% 1.13-25.89, p=0.035) and a trend for worse RFS (HR 2.94, 
95% CI 0.94-9.24, p=0.064). 
Conclusions: This is the largest set of TETs ever studied for PD-
L1 expression to our knowledge and the first to be correlated with 
clinical data. All TETs expressed PD-L1 in our TET TMA. Though 
benign thymus also stained for PD-L1, TETs stained more intensely 
for PD-L1. PD-L1 expression is a potential biomarker for benefit to 
anti-PD1/PD-L1 therapies. Our findings lend support to a clinical 
trial targeting PD1/PD-L1 in this rare tumor type.
Disclosure: No significant relationships.
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Background: Thymic epithelial neoplasms (TENs) are rare 
mediastinal lesions with variable malignant potential and limited 
therapeutic options. Compounds targeting immune inhibitory 
molecules (e.g. CTLA-4 and PD-1/PD-L1) have shown promising 
results opening new avenues for effective anti-cancer immuno-
therapy. Programmed Death-1 pathway is a major immune evasive 
mechanism in various solid tumors and is an active area of drug 
development. PDL11 appears to be predictive of response to drugs 
targeting the PD-1 pathway. Herein, we validated an assay for PD-
L1 measurement in formalin-fixed paraffin-embedded (FFPE) tissue 
and determined the relationship between PD-L1 levels and key 
clinico-pathological variables. 
Methods: We measured PDL-1 protein levels in 31 TENs from Yale 
New Haven Hospital between 1997-2012 represented in a tissue 
microarray (TMA). PD-L1 protein levels were determined in FFPE 
tissue samples using a Rabbit monoclonal antibody E1L3N and 
automated quantitative immunofluorescence (QIF). Antibody valida-
tion included immunoblot experiments and QIF analysis of human 
placenta and mel624-transfected with PD-L1 as positive controls. 
TENs cases with PD-L1 levels above the dynamic cut point de-
termined by using Join point software were considered as high 
expressers. Clinico-pathological variables studied included age, 
gender, tumor size, development of myasthenia gravis, recurrence, 
WHO histotype and Masaoka stage. The limited number of cases in 
the cohort and the small number of events precluded any survival 
analysis. 
Results: Results of antibody validation using immunoblot and QIF 
experiments using human placenta and mel624-transfected with 
PD-L1 are shown in figure 1. In TENs samples, PDL-1 signal was 
measured in the tumor compartment defined by pan-cytokeratin. 
11/29 (38%) patients with TENs had high PDL-1 expression. Cor-
relation with clinic-pathological variables did not show any signifi-
cant associations. (Table 1). Evaluation of PD-L1 in a larger cohort 
of TENs from Cleveland clinic is underway. 
Conclusions: PD-L1 protein levels can be reproducibly measured 
using QIF in FFPE samples. Over one third of patients with TENs 
show elevated PD-L1 protein levels. PD-L1 could be involved in 
the tumor-induced immune tolerance in patients with TENs. These 
observations support the exploration of the possible therapeutic 
role of PD-1 inhibitors in TENs.
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ADVANCES IN MICRORNAS EXPRESSION PROFILING OF 
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Background: An increasing interest is deserved to tumor-specific 
microRNA as relevant regulatory factors involved in tumor biology. 
MicroRNAs develop from pre-miRNAs to mature miRNAs, and dif-
ferent methodologies and approaches (Radovich et al, 2012 ASCO 
Annual Meeting) are currently applied to characterize relevant 
microRNAs in Thymic Epithelial Tumor (TET). Our aim was to char-
acterize whether different mature MicroRNA (miRs) are expressed 
in Thymoma (T) vs Thymic carcinoma (C) and in different WHO 
subtype subgroups. According to our previous data (ITMIG Annual 
Meeting, Bethesda 2013), 14 miRs were found significantly dereg-
ulated (9 up- and 5 down-regulated) in TET vs Normal (N) matched 
thymus. 
Materials and methods: MicroRNA expression profiling was per-
formed by microarray analysis of Formalin Fixed Paraffin Embedded 
(FFPE) tissue from two patient cohorts (54 thymic tumor samples 
and 12 matched normal counterparts). Scanning and image analy-
sis were performed by Agilent DNA Microarray Scanner . Following 
to the TET vs N comparison already presented, we compared the 
miR signature of T vs C, and the miR signature of WHO histotype 
subgroups (A/AB/B1 vs B2/B3 vs C) characterized by well know 
different clinical behavior according to literature data (Okumura et 
al 2002, Ströbel et al 2010, Harnath et al 2012). Reverse Transcrip-
tion and RT-qPCR quantification of miRs were performed to validate 
selected miR expression. Unsupervised two-way hierarchical clus-
tering and Principal Component Analysis were applied to evaluate 
the data. In silico prediction pathway analysis on deregulated miRs 
in tumor vs normal samples was performed using Diana miR-path 
program. 
Results: Commonly deregulated miRs in distinct WHO histotype 
subgroups vs N tissue were found as well as specifically deregulat-
ed miRs in clinically distinct histotype subgroups and in Thymoma 
(T) vs Carcinoma (C) (Ganci et al, 2014). Particularly, by comparing 
the miR signature of specific histotype groups vs normal tissues 
(A/AB/B1 vs N, B2/B3 vs N, C vs N,) we identified a group of 
9 most significant miRs in a group of 22 common deregulated 
microRNA. Moreover, we evidenced 15 miRNAs (11 down- and 
4up-regulated) distinguishing T vs C. The differential expression of 
three such miRNAs (miR-128, miR-142-5p and miR-181c-5p) was val-
idated by RT-qPCR in a subgroup of representative samples . Next, 
we performed comparisons between TET histotype subgroups. In 
particular we compared C vs B2/B3, or C vs A/AB/B1 or B2/B3 vs 
A/AB/B1 subtypes, thus identifying miRNAs differently associated 
to histotype groups. By in silico pathways prediction analysis, cell 
adhesion and motility pathways as well as cancer phenotype- re-
lated pathways appear to be targeted from deregulated miRs. It 
is worth to note that, among miRs down-regulated in thymic car-
cinoma, we found some miRs putatively targeting BIRC3, SCYA20 
and MYC, a group of thymic carcinoma-associated genes recently 
identified by Huang et al. (2013). 
Conclusion: Our data indicate that TET are characterized by a 
complex molecular miR network. MiR deregulation may contribute 
to the different oncological behavior of thymoma subtypes and 
thymic carcinoma.
Disclosure: No significant relationships.
Keywords: Thymic carcinoma, Thymoma, Thymic epithelial tu-
mors, MicroRNA
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GENETIC PROFILING OF THYMIC CARCINOMA USING TAR-
GETED NEXT-GENERATION SEQUENCING
Masayuki Shitara, Katsuhiro Okuda, Ayumi Suzuki, Tsutomu Tatem-
atsu, Yu Hikosaka, Satoru Moriyama, Hidefumi Sasaki, Motoki Yano, 
Yoshitaka Fujii  
Nagoya City University Hospital, Oncology, Immunology And Sur-
gery, Aichi-ken/JAPAN
Background: Thymic carcinoma is a rare tumor of thymic ep-
ithelial origin. Several efforts have been made to identify the 
tumorigenesis of thymic carcinoma, but little is known about the 
molecular mechanism. There is no effective treatment except for 
complete resection, and the prognosis of advanced cases is poor. 
Recently, sequencing technology has progressed remarkably. 
Next-generation sequencing has enabled whole-exome sequencing 
and targeted sequencing more easily than before. This method is 
effective and ideal for rare tumors like thymic carcinoma to analyze 
the molecular mechanism of oncogenesis. To identify the muta-
tions associated with tumorigenesis, we analyzed genetic profile of 
thymic carcinoma using targeted Next-Generation Sequencing. 
Methods: This study included 12 thymic squamous cell carcinoma 
including 10 tumor / normal tissue pairs. DNA was extracted from 
fresh frozen tissue. We performed targeted sequencing about 409 
cancer related genes, using Ion AmpliSeq Comprehensive Cancer 
Panel and Ion PGM Sequencer (Life Technologies). 
Results: The individual sample underwent on average 4,881,951 
mapped sequence reads with a 114 bp mean read length. The 
average base coverage depth was 311 reads, and uniformity of 
coverage was 92.8%. Sequencing identified 1,039 variants in 294 
genes per sample on average, and we filtered the variants using 
Ingenuity Variant Analysis (QIAGEN) and compared the sequence of 
the tumor to the matched normal tissue. And then, we excluded the 
SNVs which are Tolerated in SIFT, Benign in PolyPhen-2, and Neu-
tral in PROVEAN. In ten tumor / normal pairs, candidate mutations 
were identified in 9 of 10 patients. We confirmed 25 mutations in 
24 genes, including six tyrosine kinase genes (KIT, DDR2, PDGFRA, 
ROS1, IGF1R). One tumor contained a three-codon in-frame dele-
tion in exon 11 of KIT (c.1667_1669delTTG), resulting in a deletion 
of valine at position 556 (V556del). The mutation was confirmed by 
Sanger sequencing. 
Conclusion: We performed genetic profiling of thymic carcinoma 
using targeted next-generation sequencing. The mutation status of 
thymic squamous cell carcinoma is highly heterogeneous. We iden-
tified KIT exon 11 deletion mutation in one case. It’s an activating 
mutation of KIT and this mutation is sensitive to Imatinib in patients 
with GIST and thymic carcinoma.
Disclosure: No significant relationships.
Keywords: sequencing, Thymic carcinoma
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THYMOMA PATIENTS WITH PLEURAL DISSEMINATION: NA-
TIONWIDE RETROSPECTIVE STUDY OF 136 CASES IN JAPAN
Katsuhiro Okuda1, Motoki Yano1, Ichiro Yoshino2, Masahiko Higashi-
yama3, Meinoshin Okumura4, Kenji Suzuki5, Masanori Tsuchida6, 
Jitsuo Usuda7, Hisashi Tateyama8, Satoru Moriyama1, Yuji Haneda1, 
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1Nagoya City University Hospital, Oncology, Immunology And 
Surgery, Aichi-ken/JAPAN, 2Graduate School Of Medicine, Chiba 
University, General Thoracic Surgery, Chiba/JAPAN, 3Osaka Medical 
Center For Cancer And Cardiovascular Diseases, Thoracic Surgery, 
Osaka/JAPAN, 4Osaka University Graduate School Of Medicine, De-
partment Of General Thoracic Surgery, Suita, Osaka/JAPAN, 5Jun-
tendo University School Of Medicine, General Thoracic Surgery, 
Tokyo/JAPAN, 6Niigata University Graduate School Of Medical And 
Dental Sciences, Thoracic And Cardiovascular Surgery, Niigata/JA-
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sugai Municipal Hospiral, Pathology, Aichi/JAPAN
Background: Thymoma is a rare mediatinal tumor with reltively 
slow growth. However, advantage-stage cases with pleural dis-
semination are occasionally encountered. The outcome of surgical 
resection for thymomas with pleural dissemination has not been 
clearly determined. 
Methods: We retrospectively investigated the clinical records of 
2,835 patients with thymic epithelial tumors that were treated from 
1991 to 2010 in 32 institutions that participated in the Japanease 
Association for Research on Thymus. In this study, we analyzed the 
clinico-pathologic factors and prognosis of thymoma patients with 
plearal dissemination who underwent surgical resection. 
Results: The thymomas with pleural disseminations numbered 
148 cases (5.2% in the 2,835 thymic epithelial tumors). Surgical 
resection was performed in 136 cases. Pathologic Masaoka stages 
were classified as 4A (n=118) and 4B (n=18). In Masaoka stage 
4A disease, the small number of disseminated pleural nodules 
(10 or fewer) was related to the curative resection. The prognosis 
was also better in these cases than in those with greater than 
10 disseminated pleural nodules (certified during the operation; 
p=0.0057). Patients who underwent macroscopic total resection 
of disseminated nodules had a better prognosis than those with 
residual tumors (p=0.037). In stage 4A cases with complete resec-
tion (n=42), the efficacy of adjuvant chemotheray, radiotherapy, or 
both was not demonstrated. 
Conclusions: Macroscopic total resection of tumors appears to 
be a promising prognostic factor in Masaoka stage 4A thymomas. 
The number of disseminated pleural nodules correlated with resect-
ability.
Disclosure: No significant relationships.
Keywords: macroscopic total resection, surgical resection, pleu-
ral dissemination, Thymoma
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SURGICAL MANAGEMENT OF RECURRENT THYMIC TU-
MORS:AN ANALYSIS BASED ON THE JAPANESE NATION-
WIDE DATABASE
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Background: There is no standard treatment for recurrent thymic 
epithelial tumors. Although the efficacy has not been validated 
based on the large series studies, surgical resection is sometimes 
employed for patients with recurrent thymic tumors. The aim of 
this study was to evaluate the surgical outcomes for recurrent thy-
mic epithelial tumors based on the Japanese nationwide database. 
Methods: A Japanese nationwide registry study of thymic epithe-
lial tumors was carried out by the Japanese Association for Re-
search on the Thymus (JART). From the database of patients whose 
thymic epithelial tumors were treated surgically from 1991 through 
2010, the cohort who developed recurrence after the initial resec-
tion was extracted. Clinicopathological factors were reviewed, and 
the prognostic factors for postrecurrence survival of re-resected 
cases were examined. 
Results: Twenty-eight hundred and thirty-five patients who under-
went surgical resection of thymic epithelial tumors were registered 
to the database. Among these patients, 420 (14.8%) experienced 
recurrence. One hundred and sixty-two patients were treated sur-
gically (the surgery group) and 243 were treated non-surgically for 
recurrent disease (the non-surgery group). In fifteen patients, pres-
ence of surgical treatment was unknown. The median follow-up pe-
riod after diagnosis of recurrence was 59.8 months among those 
405 patients and 73.3 months among the 267 surviving patients. 
The 5- and 10-year postrecurrence survival rates were 82.7% and 
68.2%, respectively, in the surgery group and 43.5% and 25.4%, 
respectively, in the non-surgery group (p < 0.001). An analysis of 
the completeness of re-resections showed a survival advantage 
among the patients treated with R0-1 and R2 resections compared 
to that observed in the non-surgery group (p < 0.001, p = 0.004). 
A significant survival advantage was also noted among the patients 
treated with R0-1 resection compared to that observed in the 
non-surgery group for thymomas and thymic cancers, resepectvely 
(p < 0.001, p = 0.014). Meanwhile, survival of the patients treated 
with R2 resection was intermediate between that with R0-1 resec-
tion and that in the non-surgery group for thymomas, although 
the difference between the patients treated with R2 resection and 
the non-surgery group was not significant for either histology (p = 
0.143 and 0.809, respectively). According to univariate analyses, 
female sex as well as the early pathological Masaoka stage, WHO 
histologic type (non-thymic cancer), absence of preoperative 
treatment and short disease-free interval (DFI) was significantly 
favorable factors for survival in the surgery group. And according 
to the multivariate analysis, the WHO histologic type and DFI were 
identified to be independent prognostic factors. 
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Conclusions: The surgical outcomes of recurrent thymic epithelial 
tumors are favorable in selected patients. The role of re-resection 
may be limited in the setting of thymic cancer and/or a short DFI.
Disclosure: No significant relationships.
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DOES THE WHO HISTOLOGICAL CLASSIFICATION PREDICT 
OUTCOMES AFTER THYMOMECTOMY?
Francesco Guerrera1, Erino Angelo Rendina2, Federico Venuta2, 
Stefano Margaritora3, Ottavio Rena4, Enrico Ruffini1, Marco Luc-
chi5, Pier Luigi Filosso6  
1University Of Torino, Torino/ITALY, 2Sapienza University Of Rome, 
Fondazione Eleonora Lorillard Spencer Cenci, Roma/ITALY, 3Catholic 
University “Sacred Heart” Rome, Roma/ITALY, 4”Amedeo Avogadro” 
University Novara, Novara/ITALY, 5University Of Pisa, Pisa/ITA-
LY, 6University Of Torino, Thoracic Surgery, Torino/ITALY
Background: The World Health Organization (WHO) thymoma 
histological classification clinical value remains controversy. In this 
study, we evaluated its prognostic significance in patients with 
thymoma treated with radical intent. 
Methods: Six high-volume Italian Thoracic Surgery Institutions 
collaborated with their own retrospective anonymized datasets. 
Demographic, clinical, pathological and treatment data were exam-
ined. A WHO histological classification (WHO-HC) collapsed scheme 
(A/AB and B1/B2 types merged) was proposed and compared to 
the traditional one. Predictors of survival were assessed using Cox 
model with shared frailty. Competing-risk regression models were 
performed to identify the association between individual factors 
and cumulative incidence of recurrence (CIR). 
Results: Between 1990 and 2011, 750 thymomas were operated 
in participating Centres. Myasthenia Gravis was observed in 363 
(48%) patients. A complete resection was achieved in 676 (91%) 
cases. One hundred and nine patients (15%) had a WHO-HC A type, 
166 (22%) AB, 179 (24%) B1, 158 (21%) B2 and 135 (18%) B3, 
respectively. The 5-year OS (Fig.1) and CIR (Fig.2) for all cases was 
91% and 0.11, respectively. Five-year survival rates by WHO-HC in 
collapsed scheme were A/AB 93%, Early-B 90% and Advanced-B 
85%. Masaoka stage only, demonstrated to be an independent pre-
dictor for survival and recurrence. WHO-collapse scheme showed a 
weak significance in influencing recurrence development (P= 0.09). 
Conclusions: Our results put in evidence a WHO-HC lack of signifi-
cance in influencing prognosis, even if proposed collapsed scheme 
revealed a good stratification of risk to relapses and better correla-
tion with patients’ clinical characteristics
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IMPACT OF THE ITMIG CRITERIA ON DIAGNOSIS IN THE 
FRENCH NETWORK OF THYMIC EPIHELIAL TUMOURS. 
Thierry Jo Molina1, Lara Chalabreysse2, Vincent Thomas De Mont-
preville3, Anne De Muret4, Véronique Hofman5, Sylvie Lantuejoul6, 
Marie Parrens7, Marie-José Payan8, Isabelle Rouquette9, Véronique 
Secq8, Nicolas Girard10, Benjamin Besse11, Alexander Marx12  
1Ap-Hp; Université Paris Descartes, Sorbonne Paris Cité, Pathol-
ogy, Necker Enfants Malades Hospital, Paris/FRANCE, 2Hôpital 
Louis-Pradel, Département De Pathologie, Lyon/FRANCE, 3Centre 
Chirurgical Marie Lannelongue, Pathology, Le Plessis Robinson/
FRANCE, 4Chu De Tours, Département De Pathologie, Tours/
FRANCE, 5Hôpital Pasteur, Chu De Nice, Laboratoire De Pathologie 
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versitaire Médical De Mannheim, Université De Heidelberg, Institut 
De Pathologie, Mannheim/GERMANY
The French National Cancer Institute (INCa) has promoted since 
2012 the constitution of a nationwide network for thymic epithelial 
tumors (TET), “RYTHMIC”, with a national multidisciplinary tumor 
board. Systematic review (after the board) of all patients’ slides 
has been performed by a panel of expert histopathologists, of 
whom three had been involved in the ITMIG histopathological pro-
posals linked to the 2004 WHO classification. In each case, addi-
tional immunohistochemistry was performed systematically with 
antibodies against CD5, CD20, Cytokeratins (KL1 or AE1/AE3), 
TdT, and if needed p63, CD117, CD1a; diagnosis was made by con-
sensus on multihead microscope and videoprojection. 
 
We report the results of the first 125 consecutive cases that were 
included in the French Pathology Network RYTHMIC-Pathology. 
Cases were classified for histology and stage whenever it was 
possible, taking into account WHO 2004 and ITMIG proposals for 
histological typing and staging. There were complete concordance 
with the initial pathological and stage diagnoses in 74 cases (59%). 
39 cases (31%) were discordant considering either stage and/or 
histology. In 12 cases (10%), there were strong difficulties for the 
panel for a consensus diagnosis.
Major discrepancies between initial and panel diagnoses were ob-
served in 4 cases for which treatment impact concerned adjuvant 
radiotherapy : initial thymic carcinoma with a thymoma A panel 
diagnosis; initial AB stage II with a panel AB stage III diagnosis; 
Initial B3 stage IIB with a panel Thymic carcinoma stage III; initial 
micronodular thymoma IIB with a panel Thymic carcinoma stage 
IIB. Minor discrepancies mainly concerned downstaging stage IIA 
to panel stage IIB (5 cases), upstaging stage IIB to panel stage 
IIA (3 cases), initial diagnosis of B1 with a B2 panel diagnosis (5 
cases), initial B2 with a B2/B3 diagnosis (4 cases), initial B2 to AB 
(3 cases).
Difficult cases without strong panel consensus were mainly linked 
to the discussion between B3 and thymic carcinoma (8 cases) 
with some of the cases classified as ”B3/Thymic squamous cell 
carcinoma borderline TET”. Rare cases (3) concerned differential 
diagnosis between type A and B3 or between type AB and type B 
thymoma.
Our series underline that panel diagnosis and ITMIG proposals may 
modify staging and histotyping of TET by defining more precisely 
the histological and stage criteria. Furthermore, our series demon-
strate the importance of CD5, CD20 and CD117 staining for the 
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correct classification of TET. Our results suggest the relevance 
of an expert panel diagnosis for better decision-making about 
post-operative radiotherapy to avoid over- or undertreatment of  
the patients.
Disclosure: No significant relationships.
Keywords: diagnostic, Thymic epithelial tumors, histopathology, 
stage
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O3.01
CLINICAL FEATURES OF POSTTHYMECTOMY MYASTHENIA 
GRAVIS
Mi Kyung Bae1, Go Eun Byun2, Chang Young Lee2, Kyung Young 
Chung2  
1Seoul National University Bundang Hospital, Thoracic And Cardio-
vascular Surgery, Seongnam-si/KOREA, 2Yonsei University College 
Of Medicine, Thoracic And Cardiovascular Surgery, Seoul/KOREA
Objective: The aim of this study was to assess the clinical fea-
tures of the patients with myasthenia gravis occurring after resec-
tion of thymoma. 
Methods: Between 1986 and 2012, a total of 391patients un-
derwent resection of thymoma, excluding patients with type C 
thymoma and patients who underwent incomplete resection. We 
retrospectively reviewed the patients who were diagnosed as my-
asthenia gravis after thymoma resection. 
Results: Postthymectomy myasthenia gravis was found in 11 
(2.8%) of 391 thymoma patients who received complete resection. 
The patients included 9 male and 2 female with a median age 
of 42 (range, 27~60) years at the time of thymoma resection. 
Masaoka-Koga stages of initial thymomas were stage I in 7 pa-
tients, stage IIb in 1 patient, stage III in 1 patient and stage IVa in 
2 patients. WHO histologic types were type B1 in 4 patients, type 
B2 in 4 patients, type AB in 1 patient, type B3 in 1 patients and 
type B2+B3 in 1 patient. The interval between thymectomy and 
the onset of myasthenia gravis was 5 to 96 months. There were 
2 patients (0.7%) of postthymectomy myasthenia gravis in the 
extended thymectomy group (n=279) and 9 patients (8.0%) in the 
limited thymectomy group (n=112); resection of the thymoma with 
the surrounding thymus and fatty tissue, leaving residual thymic 
tissue. Six patients (54.5%) of 11 patients had thymoma recurrence 
at the time of myasthenia gravis diagnosis. 
Conclusion: The prevalence of postthymectomy myasthenia 
gravis is higher in the patients underwent limited thymectomy than 
the patients underwent extended thymectomy. In addition, more 
than half of patients with postthymectomy myasthenia gravis had 
thymoma recurrence. Therefore, postthymectomy might be caused 
by the remnant thymic tissue after thymoma resection or thymoma 
recurrence.
Disclosure: No significant relationships.
Keyword: postthymectomy myasthenia gravis
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IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE 
POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME
Rossana Berardi1, Alessandro Brunelli2, Silvia Pagliaretta1, Vittorio 
Paolucci1, Alessandro Conti3, Gaia Goteri4, Majed Refai2, Cecilia 
Pompili2, Giulia Marcantognini1, Francesca Morgese1, Zelmira Bal-
latore1, Agnese Savini1, Mariagrazia De Lisa1, Miriam Caramanti1, 
Matteo Santoni1, Paola Mazzanti1, Azzurra Onofri1, Armando Sabba-
tini2, Stefano Cascinu1  
1Università Politecnica Delle Marche, Clinica Di Oncologia Medica, 
Ancona/ITALY, 2Ospedali Riuniti Di Ancona, Chirurgia Toracica, Anco-
na/ITALY, 3Università Politecnica Delle Marche, Clinica Di Urologica, 
Ancona/ITALY,4Università Politecnica Delle Marche, Anatomia Pato-
logica, Ancona/ITALY
Background: we aimed to analyze genotypes 
of VEGF-A, KDR, Flt4, PDGFRα, HIF-1α and ERCC1 in thymomas and 
thymic carcinomas and their potential correlation with the risk of 
thymic tumors and/or with the outcome of these patients. 
Methods: The genomic DNA of 57 consecutive patients (43 thy-
momas and 14 thymic carcinomas) who underwent total thymec-
tomy at our Institution was extracted from paraffin-embedded 
tissue. We selected polymorphisms in the following genes: HIF1-α 
(rs2057482T>C, rs1951795A>C, rs2301113C>A, rs10873142C>T, 
rs11158358G>C, rs12434438G>A, rs11549465C>T, rs-
11549467G>A), VEGF-A (rs2010963G>C, rs699947A>C), VEG-
FR-2 (rs2305948C>T, rs1870377T>A), VEGFR-3 (rs307826T>C, 
rs307821C>A), PDGFR-α (rs35597368C>T) and (ERCC1 
(rs11615A>G). Gene polymorphisms were determined by Real-Time 
PCR using TaqMan assays. 
Results: The allele frequency of PDGFR-α rs35597368 
T was significantly higher than general population (94.7% 
vs 86.7%, p=0.036), while the frequency of alleles HIF1-α 
rs2057482C (78.1% vs 90.3%), rs1951795C (69.3% vs 86.7%), 
rs2301113A (69.6% vs 82.7%), rs10873142T (70% vs 86.7%), 
rs11158358C (75.4% vs 88.2%), rs12434438A (66.7% vs 84.5%), 
rs11549465C (85.1% vs 92.5%) were significantly lower than in 
general population. VEGFR-3 rs307821C was significantly higher in 
thymomas vs. thymic carcinomas (79.5% vs 72%, p=0.0371). The 
following factors were significantly correlated with a better overall 
survival: VEGFR-3 rs307826C, VEGFR-2 rs1870377A, PDGFR-α 
rs35597368T/C, HIF1-α rs2301113C, rs2057482C/T, rs1951795C, 
rs11158358G/C and rs10873142T/C, ERCC1 rs11615A (p<0.05). 
Conclusion: Our results suggest, for the first time, that inherited 
abnormalities in PDGFR-α, HIF-1α and VEGFR-3 pathways influence 
the risk and aggressiveness of thymic tumors. These results 
should be prospectively validated in order to optimize the diagnosis 
and treatment of these patients.
Disclosure: No significant relationships.
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O3.03
EXPRESSION OF RAGE AND HMGB1 IN TETS, THYMIC  
HYPERPLASIA AND REGULAR THYMIC MORPHOLOGY
Bernhard Moser1, Stefan Janik1, Ana Iris Schiefer2, Leonhard Mül-
lauer2, Chirstine Bekos1, Anke Scharrer2, Michael Mildner3, Ferenc 
Rényi-Vámos4, Walter Klepetko1, Hendrik Ankersmit5  
1Medical University Vienna, Thoracic Surgery, Vienna/
AUSTRIA, 2Medical University Vienna, Pathology, Vienna/
AUSTRIA, 3Medical University Vienna, Dermatology, Vienna/
AUSTRIA, 4National Institute Of Oncology, Thoracic Surgery, Buda-
pest/HUNGARY, 5Medical University Vienna/Christian Doppler Lab-
oratory For Diagnosis And Regeneration Of Cardiac And Thoracic 
Diseases, Thoracic Surgery, Vienna/AUSTRIA
Recently, a role of the receptor for advanced glycation endprod-
ucts (RAGE) in myasthenia gravis was described. RAGE and its 
ligand high mobility group box 1 (HMGB1) play key roles in autoim-
munity and cancer. To test whether these molecules are involved in 
patients with thymic abnormalities we applied immunohistochem-
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ical analysis in 33 cases of thymic epithelial tumors, comprising 
27 thymomas and 6 thymic carcinomas, and 21 nonneoplastic 
thymuses. Both molecules were detected in neoplastic epithelial 
cells: RAGE staining was most intense in WHO type B2 thymomas 
and thymic carcinomas (p<0.001). HMGB1 nuclear staining was 
strongest in A and AB, and gradually less in B1=B2>B3>thymic 
carcinoma (p<0.001). Conversely, HMGB1 cytoplasmic staining 
intensities were as follows: A and AB (none), B1 (strong), B2 (mod-
erate), B3 and thymic carcinoma (weak); (p<0.001). Fetal thymic 
tissue showed a distinct expression of RAGE and HMGB1 in sub-
capsular cortical epithelial cells which was found in 50% of myas-
thenic patients. Furthermore RAGE and HMGB1 were expressed in 
thymocytes, macrophages, Hassall’s corpuscles, thymic medulla, 
and germinal center cells in myasthenic patients. Immunohisto-
chemistry results were complemented by systemic measurements 
(immunosorbent assay): serum levels of soluble RAGE were signifi-
cantly reduced in patients with epithelial tumors (p=0.008); and in 
invasive tumors (p=0.008). Whereas RAGE was equally reduced 
in thymic hyperplasia and epithelial tumors (p=0.003), HMGB1 
was only elevated in malignancies (p=0.036). Results were most 
pronounced in thymic carcinomas. Thus, RAGE and HMGB1 are 
involved in the (patho-)physiology of thymus, as evidenced by dif-
ferentiated thymic and systemic expression patterns that may act 
as diagnostic or therapeutic targets in autoimmune disease and 
cancer.
Disclosure: No significant relationships.
Keywords: regular thymic morphology, TETs, HMGB1, RAGE
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GLUT-1 IMMUNOHISTOCHEMICAL EXPRESSION IN THYMIC 
EPITHELIAL TUMORS ACCORDING TO WHO HISTOLOGICAL 
TYPE
Pauline Quilot1, Thierry Jo Molina2, Lara Chalabreysse3, Anne De 
Muret4, Véronique Hofman5, Sylvie Lantuejoul6, Marie Parrens7, 
Marie-José Payan8, Isabelle Rouquette9, Véronique Secq8, Nicolas 
Girard10, Alexander Marx11, Benjamin Besse12, Vincent Thomas De 
Montpréville1  
1Centre Chirurgical Marie Lannelongue, Département De Pathologie, 
Le Plessis Robinson/FRANCE, 2Ap-Hp; Université Paris Descartes, 
Sorbonne Paris Cité, Pathology, Necker Enfants Malades Hospital, 
Paris/FRANCE, 3Hôpital Louis-Pradel, Département De Pathologie, 
Lyon/FRANCE, 4Chu De Tours, Département De Pathologie, Tours/
FRANCE, 5Hôpital Pasteur, Chu De Nice, Laboratoire De Pathologie 
Cellulaire Et Expérimentale, Nice/FRANCE, 6Chu De Grenoble, 
Département D’Anatomie Et De Cytologie Pathologiques, Greno-
ble/FRANCE, 7Chu De Bordeaux, Département De Pathologie, 
Bordeaux/FRANCE, 8Hôpital Nord, Aphm, Laboratoire D’Anatomie 
Pathologique, Marseille/FRANCE, 9Chu Rangueil, Service D’Anato-
mie Pathologique, Toulouse/FRANCE, 10Hôpital Louis-Pradel, Hospic-
es Civils De Lyon, Département Des Maladies Respiratoires, Lyon/
FRANCE, 11Centre Universitaire Médical De Mannheim, Université De 
Heidelberg, Institut De Pathologie, Mannheim/GERMANY, 12Institut 
Gustave Roussy, Département De Médecine, Villejuif/FRANCE
Background: Expression of glucose-transporter-1 (Glut-1) has 
been reported as a useful marker for the differential diagnosis 
between B3 thymomas and thymic carcinomas. Rythmic-pathology 
is a group of expert pathologists reviewing thymic epithelial tumors 
that are clinically discussed at French national multidisciplinary 
tumor boards. 
Methods: Immuno-histochemical expression of Glut-1 was 
reviewed by the Rythmic-pathology group in a series of 94 suc-
cessive cases with confirmed diagnosis from surgical specimen. 
Immunostaining was performed, with polyclonal rabbit antibody 
(RP128-05 Diagnostic-biosystems), on a whole section of one 
representative paraffin block from each case. Pattern and intensity 
(strong/moderate/weak) of Glut-1 expression were assessed and 
compared in each WHO histological subtype. In cases with com-
bined histology, only the main subtype present on the slide was 
considered. Erythrocytes were used as positive internal controls. 
Results: Expression was membranous and cytoplasmic, and 




A diffuse, moderate or strong staining was observed in most 
thymic carcinomas (C, 20/23). In B3 thymomas and cases with 
intermediated features between B3 thymoma and thymic carcino-
ma, a strong or moderate zonal staining was observed at distance 
from vessels and fibrous septa (9/11). This pattern sometimes 
created the aspect of an anastomosing network in large cellular 
lobules.In B1 thymomas, immunostaining highlighted foci of med-
ullary differentiation and was otherwise restricted to scattered 
cells (7/9). B2 thymomas (n=25) were heterogeneous with a 
spectrum of patterns between those of B1 and B3 thymomas.
 
Type A thymomas presented diffuse and weak positivity (3/5) 
except for one aggressive case with lung invasion in which diffuse 
positivity was moderate/strong. In AB thymomas (n=17), immunos-
taining was observed in spindle cell areas and ranged from weak 
and focal positivity, to diffuse positivity. In micronodular thymo-
S221Copyright © 2014 by the International Association for the Study of Lung Cancer
ITMIG 2014 Abstracts Journal of Thoracic Oncology  •  Volume 9, Number 10, Supplement 4, September 2014
mas (n=3), epithelial cells were negative or weakly positive, while 
B-lymphocytes were weakly positive and follicular dendritic cells 
were strongly highlighted. A single metaplastic thymoma displayed 
diffuse and moderate positivity. 
Conclusion: The pattern of Glut-1 expression globally depends on 
histological types. However, in our experience, the immunostaining 
heterogeneity does not allow a definite sub-classification in every 
single case. A comparative study of Glut-1 expression in aggres-
sive versus conventionnal type A thymomas appears warranted.
Disclosure: No significant relationships.
Keywords: Thymic carcinome, Thymoma, Immuno-histochemistry, 
Glut-1
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O4.01
COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSO-
CIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THY-
MOMA
Sukhmani Kaur Padda1, Donato Terrone2, Amanda Khuong3, Lu 
Tian4, Joel W. Neal1, Jonathan W. Riess5, Chuong D. Hoang3, Bryan 
M. Burt3, Ann N. Leung2, Joseph B. Shrager3, Heather A. Wakelee1  
1Stanford University School Of Medicine, Department Of Medicine, 
Division Of Oncology, Palo Alto/UNITED STATES OF AMERICA, 2Stan-
ford University School Of Medicine, Department Of Radiology, Palo 
Alto/UNITED STATES OF AMERICA, 3Stanford University School Of 
Medicine, Department Of Cardiothoracic Surgery, Palo Alto/UNITED 
STATES OF AMERICA, 4Stanford University School Of Medicine, De-
partment Of Health And Research Policy, Palo Alto/UNITED STATES 
OF AMERICA, 5University Of California Davis School Of Medicine, 
Department Of Internal Medicine, Division Of Hematology/Oncolo-
gy, Sacramento/UNITED STATES OF AMERICA
Introduction: Preoperative CT imaging is key for the management 
of thymic malignancies (TMs), especially in making the decision 
of whether a patient should proceed to surgery. Several groups 
have examined preoperative CT characteristics that associate with 
pathologic stage, histology, and surgical resectability. Here, we 
present Stanford University’s experience. 
Methods: The inclusion criteria was as follows: 1) diagnosis of a 
TM (thymoma, thymic carcinoma, or thymic carcinoid), 2) primary 
definitive surgery performed at Stanford, and 3) available preoper-
ative CT imaging for review. Since 1997, we identified 224 patients 
with TMs who were seen at Stanford. Of these, 106 patients had a 
TM-related surgery, 33 had missing preoperative CTs (not routinely 
uploaded until 2008), and 50 met all inclusion criteria. For those 
patients who received preoperative chemotherapy, post-treatment 
imaging was examined. The radiologist (D.T.) who was blinded to 
clinical data examined CT variables as defined by the International 
Thymic Malignancy Group (ITMIG) prospective database including: 
size of longest diameter of lesion, contour, internal density, calci-
fication, infiltration of mediastinal fat (iMF), abutment of >50% of 
mediastinal vessels, vascular endoluminal invasion, abutment/inva-
sion of adjacent mediastinal structures, elevated hemidiaphragm 
(eHD), pleural effusion, pleural nodules, mediastinal lymph node 
enlargement, and suspected extra-thoracic metastases. A propor-
tional odds regression was used to analyze the univariate associ-
ation of these variables with pathologic Masaoka-Koga stage and 
WHO histology (low-risk=A/AB/B1; intermediate-risk=B2/atypical 
carcinoid; and high-risk=B3/C). P-value <0.05 significant. A Lasso 
regularized general transformation model was used to develop a 
prediction model for staging with all variables. 
Results: Of the 50 TMs, there were 20 pathologic stage I, 4 IIA, 
5 IIB, 12 III, 6 IVA, and 3 IVB and 21 low-risk histologies, 15 inter-
mediate-risk and 14 high-risk. In a univariate analysis for stage, 
the following CT characteristics were associated with a higher 
stage: invasion of mediastinal structures OR=4.11/p=0.026), vas-
cular endoluminal invasion (OR=12.43/p=0.001), eHD (OR 6.66/
p=0.013), and pleural nodule(s) (OR 5.07/p=0.045). There was a 
trend for higher stage with a lobulated tumor (p=0.096) and abut-
ment of mediastinal vessels (p=0.077). In a multivariate analysis 
for stage, vascular endoluminal invasion was the most important 
for predicting for a higher stage followed by eHD, pleural nodule(s), 
lobulation, invasion of mediastinal structures, and iMF. There were 
less compelling associations with histology, none of which reached 
statistical significance. In a univariate analysis, iMF (p=0.063) and 
abutment of mediastinal vessels (p=0.061) trended for associating 
with higher-risk histologies. 
Conclusions: Certain preoperative CT characteristics as defined 
by ITMIG predict for Masaoka-Koga pathologic stage in our cohort, 
particularly separating stage I/II disease from stage III/IV disease. 
Vascular endoluminal invasion appeared to be the most important 
CT characteristic in our cohort. Preoperative CT features were not 
important in predicting for histology, but this could be confounded 
by inclusion of post-neoadjuvant therapy CTs. Our study is limited 
by its retrospective nature and small sample size; however, it 
shows that a group of CT characteristics as defined by ITMIG can 
assist in the management of TMs.
Disclosure: No significant relationships.
Keyword: computed tomography, thymoma, Masaoka-Koga stage, 
WHO histology
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THE BENIGN THYMECTOMY RATE AT A QUATERNARY RE-
FERRAL HOSPITAL: DOES MRI HAVE POTENTIAL TO REDUCE 
IT?
Jeanne B. Ackman1, Stacey Verzosa2, Alexandra E. Kovach3, Abner 
Louissaint, Jr.3, Michael Lanuti4, Cameron D. Wright4, Elkan F. Halpern5 
1Massachusetts General Hospital, Harvard Medical School, Radiol-
ogy, Division Of Thoracic Imaging & Intervention, Boston/UNITED 
STATES OF AMERICA, 2Massachusetts General Hospital, Radiology, 
Division Of Thoracic Imaging & Intervention, Boston/UNITED STATES 
OF AMERICA, 3Massachusetts General Hospital, Pathology, Boston/
UNITED STATES OF AMERICA, 4Massachusetts General Hospital, 
Surgery, Boston/UNITED STATES OF AMERICA, 5Mgh Institute For 
Technology Assessment, Boston/UNITED STATES OF AMERICA
Purpose: To ascertain the benign thymectomy rate at our insti-
tution, clinical and imaging features that prompted surgery, and 
whether preoperative MRI could have averted a significant number 
of these benign thymectomies. 
Materials and Methods: The benign thymectomy rate was ascer-
tained by electronic data base query of thymectomies performed at 
from 2016-2012, yielding 160 cases, 124 of which had available im-
aging. Preoperative clinical and CT imaging features were assessed 
by review of the in-house electronic medical record by 2 thoracic 
surgeons and 2 pathology-blinded radiologists, respectively. 
Results: The benign thymectomy rate of 20.0% (32/160; CI: 14.1-
27%) and non-therapeutic thymectomy rate of 43.8% (70/160; CI: 
35.9-51.8%) were primarily due to concern for thymoma. Cysts and 
thymic hyperplasia comprised 91% of resected benign lesions (53% 
and 38% respectively). 96%(28/29) of subjects with thymic bed 
cysts or thymic hyperplasia underwent sternotomy. Comparison 
of thymic bed cysts, thymic hyperplasia, and other lesions yielded 
significant differences in morphology (p < .0001), homogeneity 
of attenuation (p < .0001), and location with respect to midline (p 
< .0001). A saccular shape was exclusive to cysts. Quadrilateral, 
triangular, bilobed, and bipyramidal shapes were exclusive to thymic 
hyperplasia. Gross fatty intercalation was 100% specific to hyperpla-
sia (p < .0001). 10/10 cysts, 3/10 hyperplasia, and 22/104 remain-
ing lesions were homogeneous in attenuation. Thymic cyst mean 
attenuation was 23 +/- 23 HU, ranging up to 58 HU. 90% (9/10) of 
thymic hyperplasia were midline in location. 50% (5/10) of thymic 
cysts were midline and 32% of other lesions were midline. 
Conclusion: Given the known superior capability of MRI to dis-
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tinguish between thymic cysts, hyperplasia, and tumor, when 
compared with CT, a preoperative MRI should be considered prior 
to thymic mass resection to exclude benign thymic cysts and hy-
perplasia, in an effort to lower the benign thymectomy rate and its 
associated morbidity.
Disclosure: No significant relationships.
Keywords: MRI, thymic hyperplasia, thymic cyst, Thymectomy
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VARIATION IN RESPONSE TO NEOADJUVANT CHEMOTHERA-
PY ACROSS WHO HISTOLOGICAL SUBTYPES OF THYMOMA
Maria Teresa Ruiz Tsukazan1, Andrew Oseran1, Randall Baldessare1, 
Jia Jennifer Ding1, Anya Litvak2, Gregory J Riely2, James Huang1  
1Memorial Sloan Kettering Cancer Center, Thoracic Surgery, New 
York/UNITED STATES OF AMERICA, 2Memorial Sloan Kettering 
Cancer Center, Thoracic Oncology, New York/UNITED STATES OF 
AMERICA
Introduction: Thymomas are rare tumors which are generally 
considered to be chemosensitive; however, the response to 
therapy can be quite variable across different patients. There is 
considerable heterogeneity among thymomas, as reflected in the 
WHO histologic classification, and we sought to assess whether 
response to chemotherapy correlated with histologic subtype.
Methods: Retrospective cohort study of patients with thymoma 
treated with neoadjuvant chemotherapy followed by surgery. Re-
sponse to therapy was evaluated using RECIST and WHO criteria.
Results: From 1994 and 2013, 71 patients with biopsy-proven 
thymoma had neoadjuvant chemotherapy followed by surgery and 
69 were evaluable. Most patients were clinical Masaoka stage III 
(n=36, 52%) or IVA (n=31,45%). The most frequent histologies 
were B2 (n=21, 30%) and B3 (n=16, 23%). The most common 
chemotherapy regimens included cisplatin, cyclophosphamide, 
doxorubicin (CAP, n=48, 70%), and platinum/etoposide (EP, 
n=14, 20%). R0 resection was achieved in 58%(n=40). Across all 
patients, overall response rate (CR+PR) was 26% by RECIST and 
30% by WHO. Overall response rates were highest in B1 histology 
(58%), followed by B2 (38%), but 0% in A and AB. Bidimensional 
tumor size reduction for CAP chemotherapy was 38%, and 25% for 
EP. Mean tumor size reduction was 48.% for B1 and 47% for B2 and 
lower for A (12%) and AB (10%), p<0.05.
Conclusion: Response to neoadjuvant chemotherapy may vary 
markedly across different histologic subtypes of thymoma. B1 
and B2 thymomas exhibited the greatest response to neoad-
juvant chemotherapy. Further studies are needed to explore 
the mechanisms underlying the variation in chemosensitivity.
Disclosure: No significant relationships.
Keywords: Neoadjuvant Chemotherapy, Thymoma
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RYTHMIC: INSIGHTS IN THE MANAGEMENT OF ADVANCED 
THYMIC EPITHELIAL TUMORS
Nicolas Girard1, Eric Pichon2, Pascal-Alexandre Thomas3, Hervé 
Léna4, Eric Dansin5, Gilbert Massard6, Gérard Zalcman7, Julien 
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Rennes/FRANCE, 5Centre Oscar Lambret, Medical Oncology, Lille/
FRANCE, 6Chru Strasbourg, Strasbourg/FRANCE, 7Chu Caen, Caen/
FRANCE, 8Chu Toulouse, Toulouse/FRANCE, 9Chu Rouen, Rouen/
FRANCE, 10Chru Besançon, Besançon/FRANCE,11Institut De Can-
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Introduction: RYTHMIC (Réseau tumeurs THYMiques et Cancer) 
is the French nationwide network for thymic malignancies. Starting 
January 2012, all patients diagnosed with thymic tumor had to be 
enrolled, as part of good clinical practice recommended by the 
French National Cancer Institute. 
Methods: RYTHMIC database is hosted by the French Thoracic 
Cancer Intergroup, and prospectively collects clinical, imaging, 
treatment, and follow-up data of patients discussed at national ref-
erence multidisciplinary tumor board (MTB) meetings. Data cutoff 
was June 1st, 2014 for this analysis. 
Results: Over the study period, 825 questions were raised at the 
MTB meetings, discussing the management of 627 patients with 
thymic tumor (Figure 1). Among assessable cases, Masaoka-Koga 
stage III-IV tumors accounted for 50% of cases; histology was of 
higher grade (thymoma B2, B3, C) in these cases (p<0.001). As 
previously reported, the most frequent topic requiring multidis-
ciplinary discussion was post-operative radiotherapy (279 (34%) 
questions). First-line treatment of locally-advanced disease, and 
management (diagnosis and treatment) of recurrent disease led to 
raise 174 (21%), and 163 (20%) questions at the MTB meetings, 
respectively, 197 (24%) of which were about the modalities of 
systemic treatment. The most frequently proposed chemotherapy 
regimen and targeted agent were combination of cisplatin, adria-
mycin, and cyclophosphamide (35% of cases), and sunitinib (6% of 
cases), respectively. In the majority (72%) of cases, sunitinib was 
proposed after the results of a phase II trial were presented at the 
2013 World Conference on Lung Cancer, reporting on a significant 
clinical activity of this agent in thymomas and thymic carcinomas 
(Thomas et al. J Thorac Oncol 2013;8:S268). 
Conclusion: RYTHMIC is an exhaustive registry of thymic malig-
nancies, which provides with unique insights in the management 
of advanced and recurrent thymic malignancies with systemic 
agents. Meanwhile, limited data on this subset of patients has 
been made available in the literature so far, as clinical trials were 
conducted in small numbers of patients, and existing databases 
enrolled a majority of surgically resected, early-stage tumors. Of 
more importance, RYTHMIC allows rapid implementation of new 
results in clinical practice, while ensuring patients an equal access 
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Disclosure: No significant relationships.
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Thymoma
S225Copyright © 2014 by the International Association for the Study of Lung Cancer
ITMIG 2014 Abstracts Journal of Thoracic Oncology  •  Volume 9, Number 10, Supplement 4, September 2014
 
POSTER SESSION 1 - September 5, 2014 
Poster Display Time: 10:00 – 16:00 
Poster Setup Time: 08:00 – 10:00 
Poster Take Down Time: 16:00 – 17:00
POSTER SESSION 1 - September 5, 2014 10:00-16:00
P1.01
THE BENEFITS OF THYMECTOMY IN THE EVOLUTION OF 
MYASTHENIA GRAVIS
Vilicu Crisanda1, Mihalache Oana1, Ciolca Andreea1, Istrate Bogdan2, 
Tomulescu Victor3, Sgarbura Olivia3  
1Clinical Institute Fundeni, Department Of Neurology, Bucharest/
ROMANIA, 2Katholieke University, Department Of Cardiovascular 
Diseases, Leuven/BELGIUM, 3Clinical Institute Fundeni, Dan Set-
lacec Center For General Surgery And Liver Transplant”, Bucharest/
ROMANIA
Objective: The goal of the study was to analyze the 5-year evo-
lution of patients with non-thymomatous myasthenia gravis that 
underwent thymectomy and to compare the results with the evo-
lution of the patients with non-thymomatous myasthenia that had 
conservative treatment. Methods: We used a match-pair design to 
study two groups of patients that were diagnosed with non-thymo-
matous seropositive myasthenia gravis between 2002 and 2004 in 
the Neurology Clinic of the Fundeni Clinical Institute. The first group 
(MGT) had 50 patients that underwent a thymectomy between 
the years 2002-2004. The second group (MGNT) contained also 
50 patients that had the same diagnosis as the first group and 
had conservative treatment for personal reasons. The match pair 
criteria were: sex, age at onset, type of onset, Osserman classifi-
cation stage at diagnosis and the duration of time from onset until 
positive diagnosis. The two groups were compared from the point 
of view of the QMG score, of the necessity of cortisone and anti-
cholinesterasic medication, of the complications due to the usage 
of cortisone for long periods of time, of the number of relapses 
and of the complete stable remissions at 5 years. All the thymecto-
mised patients had unilateral thoracoscopic thymectomy. 
Results: Both groups had a majority of women (MTG-88%, MGNT-
86%), young of age, 20-39 years old (MGT-70%, MGNT-68%). 
Initial ocular onset was the most frequent, being followed by the 
bulbar onset (MGT-28%, MGNT-24%) and then by the spinal onset 
(MGT-24%, MGNT-18%). From the point of view of the Osserman 
classification at diagnosis there was a predominance of class 
IIb–IIIb, for both groups. The time interval that passed between the 
onset and positive diagnosis had a medium of 11 months for both 
groups. The medium QMG score, the medium usage of cortisone 
and anticholinesterasic were significantly lower in the MGT group 
compared to the MGNT group (p<0,0005). The complete stable 
remission at 5 years was achieved in 68% of the patients in the 
MGT group compared to under 5% in the MGNT group. 
Conclusions: All the analyzed variables are arguments that prove 
the benefits of thymectomy in non-thymomatous myasthenia gravis 
with achieving the complete stable remission at 5 years for more 
than half of our patients. Thymectomy is an important link in the 
complex treatment of myasthenia gravis, with major results on long 
term.
Disclosure: No significant relationships.
Keywords: treatment, complete stable remissions, Thymectomy, 
Myasthenia gravis
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RESULTS OF EXTENDED INTRATHORACIC LYMPHADENECTO-
MY IN COURSE OF THYMECTOMY FOR THYMIC CARCINOMA.
Andrea Viti1, Luca Bertolaccini2, Alberto Terzi2  
1S. Croce E Carle Hospital, Thoracic Surgery, Cuneo/ITALY, 2Sacro 
Cuore Research Hospital, Thoracic Surgery, Negrar-verona/ITALY
Objectives: The need and extent of lymphadenectomy in course 
of thymectomy for thymic carcinomas is a matter of debate. TNM-
based classifications evidenced the prognostic relevance of nodal 
involvement. We report a series of extended intrathoracic lymph-
adenectomies (EIL) for thymic carcinomas (TC), describing the 
outcomes and its possible prognostic role.
Methods: From 2000 to 2011, 13 patients (M/F=6/7, mean age 
55.3±11.1 years) with TC underwent extended thymectomy for TC 
plus EIL (including anterior mediastinal nodes, bilateral lower and 
higher paratracheal, aorto-pulmonary-window, para-aortic nodes). 
Nodal involvement was suspected on the basis of preoperative 
work up (PET-CT scan was performed in 6 patients). Tumor char-
acteristics, surgical procedures (access type, extended resection 
rate and type), number of lymph-nodes harvested, post-operative 
complications, disease-free and overall survival are reported. 
Actuarial-survival was calculated with the Kaplan-Mayer method, 
differences in survival between groups were calculated with Log-
rank-test.
Results: 3 patients underwent neo-adjuvant chemotherapy. 
Surgical access was sternotomy (n=9), hemi-clamshell (n=3), 
cervico-sternotomy (n=1). Macroscopic complete resection was 
achieved in all cases. Extended resection was needed in 7 patients 
for a total of 10 adjunctive procedures: upper right lobectomy 
(n=1), lung wedge resection (n=3), pericardial resection+recon-
struction (n=3), anonymous vein resection and reconstruction 
(n=2), resection of pleural implants (n=1). Besides the aforemen-
tioned stations, dissection was extended to hilar nodes (2 cases), 
carinal (3), retrotracheal (3) and left prescalene lymph nodes (1). 
291 lymph nodes were removed (mean=22). Postoperative com-
plications were laryngeal paralysis (n=2), atrial fibrillation (n=2), 
pleural effusion (n=2), bleeding needing reoperation (n=1), sepsis 
(n=1). Mean post-operative stay was 7 days (range 5-14). 11 
patients underwent post-operative radiotherapy. Nine tumors pre-
sented a low-grade histology (7 well-differentiated squamous-cell 
carcinomas, 2 Mucoepidermoid carcinomas), high-grade histology 
was represented by clear cell (n=1), undifferentiated (n=1) and 
lymphoepitelioma-like carcinoma (n=2). Nodal involvement was 
confirmed in 7 cases (53%). Yamakawa N-stage was N0 (n=6), 
N1 (n=2), N2 (n=4), N3 (n=1). Multistation involvement (n=5: 2 
stations in 4 cases, and 3 stations in 1 case) and skip metastases 
(n=2) were observed. Disease-free-survival and overall-survival 
were 27±0.6 months and 36±0.9 months respectively. Recurrence 
occurred in 9 patients (5 distant, 2 regional, 2 local recurrences). 
Disease-free-survival and Overall 5-year survival rates were 42.85% 
and 57.14% respectively. N0 Patients showed a better 5-years-DFS 
and OS than N+ patients (83.3% vs. 14.3%, p=0.0040; 80.0% vs. 
28.6%, p=0.0079 respectively).
Conclusions: EIL showed that TC has a high tendency to interest 
intrathoracic lymph nodes. Since presence of nodal metastases 
affect the prognosis, preoperative work-up (including PET-CT) 
should identify nodal involvement in order to select patients that 
would benefit from multimodality treatment and eventually from 
extensive surgery.
Disclosure: No significant relationships.
Keywords: preoperative staging, extended resection, lymph-
adenectomy, Thymic carcinoma
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PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES 
PREVIOUSLY TREATED WITH CHEMOTHERAPY
Ying Liang1, Sukhmani Kaur Padda2, Jonathan W. Riess3, Robert 
West4, Joel W. Neal2, Heather A. Wakelee2  
1Sun Yat-Sen University Cancer Center, Department Of Medical 
Oncology, Guangzhou/CHINA, 2Stanford University School Of Med-
icine, Department Of Medicine, Division Of Oncology, Palo Alto/
UNITED STATES OF AMERICA,3University Of California Davis School 
Of Medicine, Department Of Internal Medicine, Division Of Hematol-
ogy/Oncology, Sacramento/UNITED STATES OF AMERICA, 4Stanford 
University School Of Medicine, Department Of Pathology, Palo Alto/
UNITED STATES OF AMERICA
Purpose: Thymic malignancies are rare, with limited published 
trials of chemotherapy activity. Pemetrexed, a multitargetedan-
tifolate, was shown to have single agent activity in a prospective 
phase II trial[1] for previously treated thymoma and thymic carcino-
ma patients. We performed a retrospective analysis of pemetrexed 
activity in patients with thymic malignancies.
Methods: Patients with unresectable histologically confirmed 
invasive, recurrent, or metastatic thymoma or thymic carcinoma 
seen at the Stanford Cancer Center between January 2005 and 
November 2013 were identified, and those who were treated with 
pemetrexed in the second line setting and beyond were included in 
this analysis.
Results: A total of 81 thymic malignancy patients were identified, 
of whom 16 received pemetrexed. There were 10 patients (62.5%) 
with thymic carcinoma and 6 patients (37.5%) with thymoma. 
Among the 6 patients with thymoma, best response was 1 (17%) 
with a partial response (PR) and 5 (83%) with stable disease (SD). 
At a median follow-up of 21.2 months, the median PFS in the thy-
moma patients was 13.8 months (95% CI, 4.9 to 22.6 months) and 
the median OS was 20.1 months (95% CI, 16.4 to 23.9 months). 
Among the 10 patients with thymic carcinoma, best response to 
treatment was 1 (10%) PR, 5 (50%) SD, and 4 (40%) had progres-
sive disease (PD). At a median follow-up of 13.5 months, the medi-
an PFS in patients with thymic carcinoma was 6.5 months (95% CI, 
0.2 to 12.8 months) and the median OS was 12.7 months (95% CI, 
2.9 to 22.5 months).
Conclusions: This small retrospective study demonstrates peme-
trexed activity and disease stabilization in thymic malignancies with 
a clinically meaningful duration, and supports previous reports of 
pemetrexed efficacy in these rare diseases. Reference: 1. Loehrer 
PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed 
in patients with recurrent thymoma or thymic carcinoma. ASCO 
Annu Meet Proc 2006; 24:7079.
Disclosure: No significant relationships.
Keywords: Thymoma, Thymic carcinoma, Chemotherapy
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CAPECITABINE PLUS GEMCITABINE AS SECOND LINE THER-
APY IN THYMIC EPITHELIAL TUMORS
Carlo Buonerba1, Vincenzo Damiano1, Margaret Ottaviano2, Piera 
Federico2, Filomena Calabrese2, Claudia Von Arx2, Stefano De Fal-
co2, Ciro Candido2, Ana Paula De Maio2, Mariateresa Micillo2, Mirella 
Marino3, Giovannella Palmieri1  
1Aou Federico Ii, Oncology, Naples/ITALY, 2Aou Federico Ii Rare 
Tumors Referal Center Campania Region, Oncology, Naples/
ITALY, 3Regina Elena National Cancer Institute - Ifo, Department Of 
Pathology, Rome/ITALY
Background: Thymic epithelial tumors (TETs) are rare malignan-
cies, with an estimated incidence of about 3 cases per 100,000 in-
habitants. No standard treatment is available for recurrent disease. 
In 2005, a multi-institutional phase II trial was started on the combi-
nation of gemcitabine and capecitabine in pretreated patients with 
TETs. Final results of this phase II study are presented.
Methods: Eligibility criteria for the study were mainly the follow-
ing: histologic diagnosis of TET by central review; at least one prior 
systemic chemotherapy treatment; progressive disease. Treatment 
consisted of oral capecitabine (650 mg/mq twice daily on days 
1–14) and i.v. gemcitabine (1000 mg/mq on days 1 and 8) every 3 
weeks. The radiographic response rate was chosen as primary end 
point and employed to calculate the study sample. Secondary end 
points were progression-free survival, toxicity, and overall survival.
Results: Thirty patients (18 men, 12 women; median age 57 
years, range 48–61 years) were enrolled in this phase II trial from 
November, 2005 to June 2013. The majority of patients (73%) 
had thymoma, while the remaining had thymic carcinoma. Of note, 
63% of patients showed disease progression within 2 months from 
the last dose of the last systemic received therapy. The most im-
portant grade 3 toxicity was neutropenia in eight patients. Twelve 
patients had a response (three complete responses and eight par-
tial responses). Among thymic carcinoma patients, we observed 
three partial responses. Median PFS was 11 months (95% CI 3–17 
months). The PFS for patients with thymoma and thymic carcinoma 
was respectively 11 months (95% CI 6–17 months) and 6 months 
(95% CI 3–11 months). Thirteen patients are dead at the time of 
the analysis (median OS, 16 months).
Conclusions: Capecitabine and gemcitabine is an highly active 
combination therapy in thymic epithelial tumors and should be rou-
tinely included in the managment of recurrent/metastatic disease.
Disclosure: No significant relationships.
Keywords: THYMIC EPITHELIAL TUMOR, capecitabine, gemcit-
abine, second line therapy
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TIME CHANGE IN MANAGEMENT AND OUTCOME FOR THY-
MIC MALIGNANCY IN CHART RETROSPECTIVE DATABASE
Wentao Fang  
Shanghai Chest Hospital, Thoracic Surgery, Shanghai/CHINA
Thymic malignancies are relatively rare and indolent disease. The 
Chinese Alliance for Research of Thymomas (ChART) retrospec-
tively collected 1693 patients treated at 10 institutions during 
1994-2012. Histology was closely related to stage, with 67.7% 
thymomas in stage I-II but 80% thymic carcinomas above stage 
III. Overall 10-year survival (OS) was 76.4%, with 17% recurrence. 
Masaoka stage, WHO histology, and complete resection were 
identified as independent risk factors for OS, while MG or adjuvant 
therapies did not affect prognosis. Comparison was made between 
two time groups (Group A:1994-2003, Group B:2004-2012), simi-
lar in sex, age, MG, staging, and histology. There was a significant 
increase in minimally invasive approaches (0% vs. 24.2%, p<0.05) 
and decrease in lateral thoracotomy (41.6% vs. 25.6%, p<0.05). 
Significant increase in complete resection was observed in thy-
mic carcinomas (62% vs. 83.3%, p<0.05), but not in thymomas 
(89.8% vs. 92.3%, p>0.05). Significantly more patients in Group 
B had surgery alone (29.9% vs. 48.5%, p<0.05), without adjuvant 
radiation (41.6% vs. 25.7%, p<0.05). This was observed in all A/
S227Copyright © 2014 by the International Association for the Study of Lung Cancer
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AB and stage I-II B1-3 thymomas. Similar change was seen in stage 
I-II thymic carcinomas, with decreased use of adjuvant chemother-
apy. Management remained similar for stage III tumors. Overall 
recurrence decreased significantly in Group B (25.4% vs. 14.5%, 
p<0.05), although follow-up was also shorter. The decrease was 
both in thymic carcinomas (53.2% vs. 35.4%, p<0.05) and thymo-
mas (16.1% vs. 9.1%, p<0.05), mainly in B1-3 (26.6% vs. 12.7%, 
p<0.01) but not in A/AB thymomas (3.1% vs. 1.9%, p>0.05). Five-
year OS were similar between the two groups in stage I-II tumors 
(95.9% vs. 92.9%, p>0.05), despite of a significant decrease in 
adjuvant radiation (57.4% vs. 25.8%, p<0.001). OS was significant-
ly increased in stage III tumors (67.1% vs. 81.5%, p<0.05). OS was 
similar in stage III thymomas (78.9% vs. 82.3%, p=0.658) though 
adjuvant radiation decreased (70% vs. 53.3%, p=0.16), owing to 
a significant increase in complete resection (73.9% vs. 89.5%, 
p=0.037). OS of stage III thymic carcinomas improved (45.8% vs. 
60.7%, p=0.077) along with increased resection rate (59.4% vs. 
75%, p=0.086). Consensus could be reached as follows: Both 
stage and histology should be considered when deciding manage-
ment strategy for thymic malignancies, and complete resection 
is of critical importance. Stage I-II tumors could be removed via 
minimally invasive procedures, with optimal result after complete 
resection and without adjuvant therapies. For stage III B thymo-
mas, improved survival is possible if complete resection could be 
achieved, and role of adjuvant radiation is still questionable. Most 
thymic carcinomas are in advanced stage. Effective induction may 
be needed to help increase resection rate and thereby, long-term 
survival.  
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EIGHT YEARS OF EXPERIENCE WITH DA VINCI ROBOTIC- 
ASSISTED THYMECTOMIES
Patrick Lauwers1, Jeroen Hendriks1, Rudolf Mercelis2, Patrick Pau-
wels3, Paul Van Schil1  
1Antwerp University Hospital, Thoracic And Vascular Surgery, Ede-
gem/BELGIUM, 2Antwerp University Hospital, Neurology, Edegem/
BELGIUM, 3Antwerp University Hospital, Department Of Pathology, 
Edegem/BELGIUM
Introduction Nowadays, Video-Assisted Thoracoscopic Surgery 
(VATS) is widely incorporated. Robotic systems, such as the da 
Vinci® System (Intuitive Surgical, Inc, US), offer an excellent 
visualization of the operative field in combination with a nearly 
unlimited range of movements of the instruments (Endowrist® 
technology). These advantages enable to perform more complex 
thoracoscopic interventions. The aim of present study is to review 
the experience at the Antwerp University Hospital with the da Vinci 
Robotic System within the field of thoracoscopic thymectomies. 
Materials and Methods This is a retrospective review of a single 
centre experience, using the da Vinci robotic system to assist in 
thoracoscopic resection of the thymus. Results Since 2003, the da 
Vinci robotic system has been implemented in our hospital; the first 
robotic assisted thymectomy was done in 2006. Since than, a total 
of 47 patients (19 males, 28 females; age 17 – 79, mean 40 years) 
underwent a da Vinci-assisted VATS thymectomy. One patient was 
converted to median sternotomy, due to severe obesity and inade-
quate single lung ventilation. Only 19 patients were admitted to the 
Intensive Care Unit (ICU), with a mean ICU stay of 1.5 days. Mean 
hospital stay was 9 days (4-29 days). There was no operative mor-
tality. The majority of the patients suffered from myasthenia gravis 
(n=27). Five patients needed plasmapheresis in the immediate 
preoperative period. Only one patient with myasthenia gravis could 
not be weaned from the ventilator in the operative theatre, but was 
extubated shortly after admission to the ICU. All other patients 
had a good recovery from anesthesia. At least 15 patients with 
myasthenia had clear improvement of their symptomatology during 
follow up (0 – 8 years, mean 3 years). After histologic evaluation, 
24 patients were found to have thymic hyperplasia, in 5 patients 
the thymus seemed to be normal, and in 2 patients a benign cystic 
lesion of the thymus was found. Sixteen patients were treated for a 
thymoma; in one patient even two separate thymomas were found. 
Seven patients with a thymoma suffered from myasthenia gravis. 
The thymoma’s were WHO type A (n=3), type AB (n=3), type B1 
(n=4) and B2 (N=7); according to the Masaoka-Koga classification 
11 patients were in stage 1, 3 patients in stage 2a and 2 in stage 
2b. The latter 5 patients were treated with adjuvant radiotherapy, 
as well as one patient were the capsula was opened (diagnosis of 
thymoma made by open surgical biopty). Recurrent disease was 
suspected in one patient, however without histological proof and 
with stable findings during follow up. All other patients remained 
disease-free (follow up 0 – 7 years, mean 2,4 years). Conclusion 
Robotic-assisted VATS thymectomy is feasible and safe. Although 
preparation for the procedure is time-consuming due to the instal-
lation and the sterile draping of the robotic system, the operative 
procedure itself is facilitated and reduced due to the excellent 
three dimensional visualization and movement of the robotic instru-
ments. Although the hospital stay seems rather long, patients and 
surgeons feel at ease with this minimal invasive procedure.
Disclosure: No significant relationships.
Keywords: da Vinci, Thymectomy, Thymoma, Myasthenia gravis
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EFFECTIVENESS OF EVEROLIMUS PLUS SOMATOSTATIN 
ANALOGS IN THYMIC EPITHELIAL TUMORS
Giovannella Palmieri1, Margaret Ottaviano1, Carlo Buonerba1, Piera 
Federico1, Filomena Calabrese1, Claudia Von Arx1, Stefano De Fal-
co1, Lucia Nappi1, Pasquale Rescigno1, Mirella Marino2, Vincenzo 
Damiano1  
1Aou Federico Ii Rare Tumors Referal Center Campania Region, 
Oncology, Naples/ITALY, 2Istituto Regina Elena Rome, Pathology, 
Rome/ITALY
Background: New options are available in heavily pretreated ad-
vanced or recurrent thymic epithelial malignancies. The mTOR com-
plex is also a potential target in TETs, as it is linked to downstream 
signaling of cytokines and growth factors involved in the biology 
of these tumors. After publication of two TET cases that showed 
a prolonged (>2 years) disease stabilization with everolimus plus 
octreotide LAR, we tested this combination in a phase II study. 
Methods: This phase II study is an open-label, nonrandomized, Ital-
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ian single center study. Adult patients with histologically confirmed 
TET, that is metastatic and measurable according to RECIST crite-
ria, were enrolled, previous chemotherapeutic regimens, including 
platinum agent as first line. Treatment consists of oral everolimus 
(10 mg daily) and octreotide LAR (30 mg every four weeks). 
Treatment is continued until RECIST progression. The primary end 
point is response rate; secondary end points are safety, progres-
sion-free survival (PFS) and overall survival (OS). Tumor assess-
ment is performed every eight weeks and safety every 14 days. 
Toxicity is assessed using the National Cancer Institute Common 
Toxicity Criteria (version 4.0). In the first stage, 15 patients have to 
be enrolled. If three or more responses are observed, the design 
calls for an additional 20 eligible patients to be accrued. 
Results: Six patients were enrolled (median age, 54 years, range 
49-58, 1 F and 5 M). Three patients with thymic carcinoma, one 
with B2 thymoma and 2 with B2-B3 were enrolled. A partial re-
sponse was observed in 2 patients, while stable disease was ob-
served in 4 patients. No grade 3-4 toxicity has been oberved. After 
a median follow up time of 3 months (range, 3-6), no patient has 
either died or progressed. 
Conclusions: Preliminary data of this ongoing phase II study are 
extremely encouraging. Mature results are awaited.
Disclosure: No significant relationships.
Keywords: target therapy, everolimus, somatostatin analogs, 
Thymic epithelial tumors
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CAPECITABINE AND GEMCITABINE AS 2ND LINE THERAPY IN 
THYMIC EPITHELIAL TUMOURS - RETROSPECTIVE DATA
Kristoffer Staal Rohrberg, Peter Meidahl Petersen, Anne Juul Chris-
tensen, Helle Pappot, Mikael Roerth, Gedske Daugaard  
University Hospital Of Copenhagen, Rigshospitalet, Dept. Of Oncolo-
gy, Copenhagen/DENMARK
Background: In a recently published phase II trial, capecitabine 
and gemcitabine (CAP-GEM) was an effective second line therapy 
in patients with thymic epithelial tumours (TETs), with an overall 
response rate of 40%. On this basis, CAP-GEM is the standard 
second line therapy for patients with TETs at our institution. The 
aim of the present study was to investigate the effect of CAP-GEM 
in the clinical setting and to compare response rate to data from a 
recently published phase II trial. 
Patients and Methods: This is a retrospective study investigating 
response rates in the first 6 patients with TETs treated with CAP-
GEM at our institution. Patients eligible for therapy with CAP-GEM 
had histologically or cytologically verified TET, were progressing 
after first line chemotherapy, had PS ≤ 2, had sufficient organ func-
tion, and could not be treated with definite surgery or radiotherapy. 
Results: The first 6 patients treated with CAP-GEM had a median 
age of 61 (range: 38-76). Three patients (50%) had type B2, two 
patients (33%) had B3 and one patient (17%) had thymic carcino-
ma. All patients had previously been treated with cisplatin, doxo-
rubicine, cyclophosphamide and vincristine. Three patients had 
previous received more than one line of systemic therapy. Patients 
received a median of 7 cycles (range: 6-11) of CAP-GEM. Partial 
response was observed in 2 patients (RR: 33%), 3 patients (50%) 
had stable disease, and one patient (17%) had progressive disease. 
One patient underwent radical surgery after 6 cycles of CAP-GEM.  
 
Conclusion: CAP-GEM is a well-tolerated regiment with a reason-
able activity as second line therapy in patients with inoperable 
TETs. We found a response rate comparable to data from a recent-
ly published phase II trial.
Disclosure: No significant relationships.
Keywords: capecitabine, gemcitabine, Retrospective, Second line 
chemotherapy
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IS DIAGNOSTIC VAT THYMECTOMY AN ACCEPTABLE FIRST-
LINE APPROACH TO THE SUSPICIOUS MEDIASTINAL MASS?
Ricky Vaja, Vijay Joshi, Alan Dawson, David Waller  
Glenfield Hospital, Thoracic Surgery, Leicester/UNITED KINGDOM
Introduction: The incidental early stage thymic mass presents a 
diagnostic challenge. Right-sided Video Assisted Thoracoscopic 
(VAT) thymectomy is an attractive but potentially morbid solution. 
The aim was to show that it can be safely applied as a first line 
modality in those with undiagnosed thymic enlargement with ac-
ceptable long-term results.
Methods: Forty-two patients were identified (23 male, median age 
53 IQR: 41-65 years) in a 14 year experience who had comput-
erised tomographic evidence of an enlarged, possibly malignant 
thymic mass but no tissue diagnosis prior to undertaking VAT 
thymectomy through a right-sided approach. The clinical outcomes 
of both benign and malignant diagnoses were compared.
Results: Pre-operative myasthenic symptoms were present in 
19 patients (45%) whilst 15 (36%) were asymptomatic. Benign 
lesions were resected in 26 patients (62%): thymic hyperpalasia 
(54%), thymic cyst (35%), lipoma (8%), and xanthogranulomatous 
inflammation (3%). Of the 16 malignant patients, 82% had thymo-
ma (two had Masaoka stage I, 10 stage II, and one stage III.), 6% 
thymic carcinoma, 6% teratoma and 6% seminoma. Eight patients 
required subsequent radiotherapy for R1 resection. The median 
hospital stay was significantly shorter in the benign group: 4 vs 5 
days (p=0.046). One patient in both groups required conversion to 
open sternotomy. There was no other significant morbidity in the 
benign group. Two patients in the malignant group had significant 
morbidity (1 myocardial infarction and 1 pulmonary embolism). In 
the malignant group, there were no cases of tumour recurrence or 
mortality at median follow up of 5.6 years (IQR: 4.2-10.2 years).
Conclusion: Right sided diagnostic VAT thymectomy is a safe and 
effective first line approach to suspected malignant thymic enlarge-
ment. At five year follow-up there were no cases of recurrence in 
the malignant group, thus R0 resection may not be a necessity in 
these cases.
Disclosure: No significant relationships.
Keywords: Thymoma, VAT, Thymectomy
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THE ASSESSMENT OF SURGICAL ACCESS TO THE EFFEC-
TIVENESS OF THYMOMA TREATMENT
Sebastian Winiarski1, Malgorzata Szolkowska2, Piotr Rudzinski1, 
Renata Langfort2, Tadeusz Orlowski1  
1National Tuberculosis And Lung Diseases Research Institute, Tho-
racic Surgery, Warsaw/POLAND, 2National Tuberculosis And Lung 
Diseases Research Institute, Pathology Dpt., Warsaw/POLAND
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Background: Thymoma is a neoplasm in which surgical resection 
is the treatment of choice. 
Methods. A group of 124 patients with diagnosis of the thymoma 
which had surgical resection in the period of time between January 
2004 and December 2013 was evaluated. Patients were devided 
in two 5- year periods 2004-2008 and 2009-2013. Overall survival 
rate was evaluated according to surgical technique and Masaoka 
staging system and was compared in periods. In first period of 
time between 2004 and 2008, 39 patients had sternotomy, 6 had 
thoracotomy and 3 had VATS thymectomy. The Masaoka staging 
in sternotomy was 4 in I, 30 in II, 4 in III and 1 in IV. In thoracotomy 
was 6 in II. In VATS thymectomy group was 1 in I and 2 in stage II. 
In second period of time between 2009 and 2013, 53 had sternot-
omy, 14 had thoracotomy and 9 had VATS thymectomy. The Masa-
oka staging in sternotomy was 7 in I, 40 in II, 3 in III and 3 in stage 
IV. In thoracotomy Masaoka distribution was 3 in I, 9 in II, 2 in III. In 
VATS group was 9 in II. Overall 92 patients (74,2%) had sternotomy, 
20 patients (16,1%) had thoracotomy and 12 patients (9,7%) had 
VATS thymectomy. The distribution of Masaoka staging system was 
15 in I (12,1%), 96 (77,4%) in II, 9 (7,2%) in III and 4 (3,2%) patients 
in stage IV. 
Results: Five-year survival rate for patients with Masaoka histo-
pathological diagnosis was: 2004-2008 I – 98,4%, II – 96,5%, III/IV 
– 90,1% and 2009-2013 I – 98,9%, II – 96,7%, III/IV – 89,3%. Five-
year survival rate in first group for patients who had sternotomy 
was 98,1%, thoracotomy – 90,2% and VATS thymectomy 82,8%. 
Whereas survival rate in second group was: sternotomy – 98,7%, 
thoracotomy 94,6%, VATS 84,8% 
Conclusion: Surgery remains the gold standard for thymoma and 
the overall survival rate is satisfying. The early-stages of thymoma 
in Masaoka staging have a better prognosis and it is confirmed in 
both periods. Although minimally invasive treatment of thymoma 
should be considered in early-stage tumors, it is still controversial 
and requires a long-term observations.
Disclosure: No significant relationships.
Keywords: Thymoma, VATS, minimally invasive thymectomy, sur-
gery
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SINGLE-CENTRE 20-YEAR EXPERIENCE WITH SURGICAL 
TREATMENT OF THYMIC TUMOURS.
Sofie Viskens1, Hans Van Veer1, Thomas Tousseyn2, Willy Coose-
mans1, Herbert Decaluwé1, Philippe Nafteux1, Paul De Leyn1, Patrick 
Schöffski3, Dirk De Ruysscher4, Dirk Van Raemdonck1  
1University Hospitals Leuven, Thoracic Surgery, Leuven/BEL-
GIUM, 2University Hospitals Leuven, Pathology, Leuven/BEL-
GIUM, 3University Hospitals Leuven, Medical Oncology, Leuven/BEL-
GIUM, 4University Hospitals Leuven, Radiation Oncology, Leuven/
BELGIUM
Background: Large single-centre institutional series on thymic 
tumours are scarce. Complete resection remains the mainstay of 
successful treatment. Characteristics and survival were reviewed 
in all patients treated in our institution between 1993-2013.
Methods: Hospital databases revealed 134 patients with patho-
logically-proven thymic tumour. Follow-up (median 63 months) was 
through patient notes and by telephone contact with the general 
practitioner.
Results: Patients were classified in Masaoka-Koga stages: I: 
37%; IIa: 10%; IIb: 10%; III: 20%; IVa: 14%; IVb: 3%; unknown: 5%. 
According to the WHO classification, pathological subtypes were 
A: 14%; AB: 19%; B1: 16%; B2: 23%; B3: 11%; thymic carcino-
ma: 17%. Parathymic syndromes were diagnosed in 45 patients: 
myasthenia gravis (84%); pure red-cell aplasia (4%); hypogamma-
globulinemia (2%); and others (9%). 124 patients (93%) underwent 
surgery with complete resection in 104 (84%). Surgical approach 
was: sternotomy (n = 79); thoracotomy (n = 35); cervicotomy (n 
= 2); other/unknown: (n = 8). In 73 patients (59%) no biopsy was 
taken prior to surgical resection, 25 were treated with induction 
chemotherapy, 36 received adjuvant radiotherapy. In hospital mor-
tality was 0.81%. 35 patients died during follow-up (13 of tumour 
or treatment-related causes). Overall and recurrence-free survival 
at 5, 10, and 15 years were 86%; 64%; 47% and 67%; 49%; and 
31%, respectively. The survival curves were significantly different 
according to the Masaoka-Koga staging (p < 0.01) and so are the 
recurrence-free survival curves according to the WHO classification 
(p < 0.05). The overall survival according to the WHO classification 
was not significantly different (p > 0.05). (Figure) There was a sig-
nificant association, using the Pearson’s Chi square test, between 
WHO classification and Masaoka-Koga stages I-IIa-IIb versus III-IVa-
IVb (p < 0.01). (Table)
Conclusions: Operability and complete resectability of thymic tu-
mours in our experience is highly correlated with prolonged overall 
and recurrence-free survival. Masaoka-Koga stage is an important 
predictor for survival and shows a significant association with WHO 
classification.  
Masaoka-Koga staging and WHO classification
WHO classification
Masaoka-Koga 
Staging A AB B1 B2 B3 TC Total
I, IIa, IIb 12 22 12 20 7 5 78
III, IVa, IVb 7 3 7 11 8 14 50
Total 19 25 19 31 15 19 128
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INDUCTION THERAPY VS INITIAL SURGERY IN ADVANCED 
THYMIC TUMORS:PERIOPERATIVE AND ONCOLOGICAL OUT-
COME
Giovanni Leuzzi1, Mirella Marino2, Gabriele Alessandrini1, Isabella 
Sperduti3, Felicita Corzani1, Enrico Melis1, Virna Cerasoli1, Daniele 
Forcella1, Sandro Carlini1, Paolo Visca2, Maria Teresa Ramieri4, Anna 
Ceribelli5, Francesco Facciolo1  
1Regina Elena National Cancer Institute - Ifo, Department Of Surgi-
cal Oncology, Thoracic Surgery Unit, Rome/ITALY, 2Regina Elena 
National Cancer Institute - Ifo, Department Of Pathology, Rome/ITA-
LY, 3Regina Elena National Cancer Institute - Ifo, Scientific Direction, 
Rome/ITALY, 4F. Spaziani Hospital, Asl Frosinone, Department Of 
Pathology, Frosinone/ITALY, 5Regina Elena National Cancer Institute 
- Ifo, Department Of Oncology, Rome/ITALY
Objective: Despite the intense debate concerning the manage-
ment of advanced thymic tumors (ATTs), no specific oncological 
strategies have been yet recommended. In this setting, we report 
our mono-centric 13-yrs-experience to investigate this issue.
Methods: From 01/2001 to 12/2013, the clinical data of 28 
patients treated for ATTs (Masaoka stages III-IV) were retrospec-
tively reviewed. Eleven potentially non-resectable patients (Group 
A) underwent induction chemotherapy followed by surgery, while 
immediate surgery was performed in 17 patients (Group B). The 
end-point was to compare the two groups on: 1) surgical resect-
ability; 2) postoperative course; 3) disease-free survival; 4) overall 
survival. The Mann-Whitney and Fisher’s exact tests were used 
to evaluate the associations. Survival analysis was performed by 
Kaplan-Meier method and log-rank test.
Results: The main features of the sample are summarized in Table 
1 (Fig.1). WHO histological classification included two A, four AB, 
one B1, ten B2, one B2/B3, three B3, six C and one NETT. Both 
groups were comparable in terms of age, gender, clinical stage, 
clinical tumor size, histology and adjuvant therapy. Length of sur-
gery was statistically longer in Group A (p=0.015). R0 resection 
was similarly achieved in both groups (p=0.99). Postop complica-
tions occurred in 8 cases of Group A and 9 of Group B (p=0.43). 
Median postoperative stay was 9 and 7 days for Group A and B, 
respectively (p=0.08). The 3-yrs overall survival was 71.4% for 
Group A and 93.3% for Group B (p=0.84, Fig.2). On the other hand, 
3-yrs disease-free survival was 40.5% and 53.7% for Group A and 
B, respectively (p=0.67, Fig.2). Statistical analysis showed Masao-
ka stage as unique predictor of relapse (p=0.03).
Conclusions: Our results suggest that initial surgery in ATTs is 
associated to similar perioperative and oncological outcome com-
pared with induction therapy plus surgery. Further studies based 
on larger series are needed to better investigate the role of multi-
modality treatment in ATTs. 
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LONG LASTING MANAGEMENT OF FUNCTIONAL NEUROEN-
DOCRINE THYMIC CARCINOMA
Margaret Ottaviano1, Claudia Von Arx1, Stefano De Falco1, Carlo 
Buonerba1, Piera Federico1, Filomena Calabrese1, Lucia Nappi1, 
Pasquale Rescigno1, Vincenzo Damiano2, Giovannella Palmieri1  
1Aou Federico Ii Rare Tumors Referal Center Campania Region, 
Oncology, Naples/ITALY, 2Aou Federico Ii, Oncology, Naples/ITALY
Background: We describe two rare tumor cases of functional neu-
roendocrine thymic carcinoma. Due to their rarity, nowadays there 
are no guide-lines for the management of this kind of neoplasia and 
the associated syndromes.
Materials and Methods: One patient was a 49-year old woman 
with a diagnosis of functional neuroendocrine small cell thymic car-
cinoma in a MEN 1 syndrome, judge inoperable. The other patient 
is a 40-years old man, with diagnosis of functional neuroendocrine 
thymic carcinoma, discovered for an associated Cushing’Syndrome 
ACTH dependent, went to no radical surgery. Both of them, were 
so candidate to a systemic therapy associated to somatostatin 
analogues to control the paraneoplastic syndrome, never interrupt-
ed. The first line chemotherapy based on Carboplatin-Etoposide did 
not reach the control disease, second line chemotherapy based on 
CAP schedule (Doxorubicin-Cisplatin-Cyclophosphamide), reached 
a complete response in the male patient. After progression dis-
ease, both of them underwent to a target therapy with everolimus 
10 mg/daily, obtaining stable disease for more than one year, and 
after other progression, they were candidate to sunitinib 50 mg/
daily, obtaining stable disease for more than one year.
Results: The female patient died after five years from diagnosis, 
the male patient is still alive, with a stable disease, after five years 
from diagnosis.
Conclusion: We present our experience of long lasting manage-
ment of functioning neuroendocrine thymic carcinoma, with the use 
of somatostatin analogues for the control of associated functioning 
syndromes and the target therapy (mTOR inhibitor and TKI inhibitor) 
as a promising new strategy of treatment.
Disclosure: No significant relationships.
Keywords: Neuroendocrine thymic carcinoma, TKI inhibitor, mTOR 
inhibitor, somatostatin analogs
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THYMIC MALIGNANCIES: CLINICAL SPECTRUM AND MULTI-
DISCIPLINARY APPROACH IN A TERTIARY CARE INSTITUTE.
Manoj Kumar Behera1, P. K. Julka1, G. K. Rath2  
1All India Institute Of Medical Sciences (Aiims), Clinical Oncology, 
New Delhi/INDIA, 2All India Institute Of Medical Sciences (Aiims), 
Radiation Oncology, New Delhi/INDIA
Aim: To evaluate the clinical presentation, combined therapeutic 
approaches and specifically the role of radiotherapy in thymic car-
cinoma.
Background: Thymic carcinomas are rare and invasive mediasti-
nal neoplasm with high risk of metastasis, differ morphologically 
and biologically and management remains still controversial. 
Locally advanced tumors have a relatively high risk of recurrence 
and decreased rates of long term survival. Multimodal aggressive 
approach can improve complete resection rates and long-term out 
comes.
Material and Methods: The clinical and pathologic data of thymic 
malignacies were retrospectively reviewed from 2005 to 2014 and 
out of 17 patients only 7 were evaluable at the time of this study. 
The presenting age group ranges from 45 to 70 years. Ten patients 
were clinically staged as Masaoka stage III. Three patients had 
brain metastasis and 2 had bony/vertebral metastasis on presen-
tation. The pathological subtypes were squamous cell carcinoma 
and poorly or undifferentiated carcinoma. The treatment modalities 
used: surgery (5), surgery followed by PORT (2), radiotherapy (3), 
chemo RT (2), and palliative therapy (5). Twelve cases were inoper-
able and received radiotherapy or chemoradiotherapy. Seven cas-
es underwent resection; total resection in 2 cases and subtotal in 
5 cases. The median dose of radical RT received was 60 Gy. Whole 
Brain RT with 30 Gy/10#/2 weeks in brain metastasis and pallia-
tive RT of 20 Gy/5#/1week or 8 Gy /1# in bony metastasis, were 
delivered. Systemic chemotherapy with cisplatin or carboplatin and 
etoposide, upto 6 cycles was the regimen used.
Results: The median survival was 38 months. Patients with brain 
and bone metastasis expired within 3-22 months. Overall survival 
was 52%. A number of cases did not report for proper follow up in 
time. Patients with complete resection and patients receiving rad-
ical RT with chemotherapy had better disease control. The recent 
case with vertebral metastasis received IMRT to the local disease 
and the bony lesion as well followed by systemic chemotherapy 
and bisphosphonate therapy having better symptom control.
Conclusion: Over the past 5-10 years radiotherapy has evolved 
from 2D to 3D Conformal to IMRT and IGRT. Conformal techniques 
have good result in terms of better coverage of target volume and 
sparing of normal tissue and better tolerance. Chemotherapy and 
Radiotherapy definitely add to overall survival, local control and 
symptomatic relief in palliative setting.Thymic malignancies need 
multidisciplinary approach but poor referral and follow up still re-
main a concern in our setup.
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EFFECTIVENESS OF VIDEOTHORACOSCOPIC THYMECTOMY 
IN MANAGEMENT OF MYASTHENIA GRAVIS.
Wojciech Zurek1, Malgorzata Bilinska2, Sebastian Szczyrba2, Witold 
Rzyman1  
1Medical University Of Gdansk, Department Of Thoracic Surgery, 
Gdansk/POLAND, 2Medical University Of Gdansk, Department Of 
Adult Neurology, Gdansk/POLAND
Myasthenia gravis (MG) is an autoimmune neuromuscular disease 
with fluctuating muscle weakness and fatigue. Muscle weakness is 
caused by circulating antibodies (Antiacetylcholine Receptor Anti-
bodies – AChRAB) that block acetylcholine receptors at the post-
synaptic neuromuscular junction, inhibiting the excitatory effects 
of the neurotransmitter acetylcholine on nicotinic receptors at 
neuromuscular junctions. The possible source of antigen for AChR-
AB are myoid cells of thymus gland. Up to 65-75% of patients have 
thymus hyperplasia, 10-30% have thymoma. Surgical removal of 
the thymus in majority of patients results in improvement of symp-
toms. There is a number of surgical approaches for thymectomy: 
transsternal, transcervical and videothoracoscopic.  
 
Aim: The aim of this paper was to analyse the effectiveness of 
videothoracoscopic thymectomy in the treatment of MG.
Material: 42 patients, aged 16 to 52 years with generalised form 
of MG according to Osserman classification, with thymic hyperpla-
sia in computerised tomography (CT) were accepted for evaluation. 
All of them had videothoracoscopic thymectomy performed in the 
years 2002 – 2013 in the Department of Thoracic Surgery, Medical 
University of Gdansk. The mean time from onset of symptoms to 
surgery was 19 months. The mean time from surgery to the clinical 
evaluation was 35 months. Two different severity scores (Osser-
man Score and Oosterhuis Index) served as criteria for the course 
of the disease. All patients had CT of mediastinum after surgery. 
The serum level of AChRAB before and after thymectomy was com-
pared. Medication before and after surgery was the other factor 
analysed.
Results: Post-operative complications were diagnosed in 5 pa-
tients (11,9%): pleural hematoma treated videothoracoscopically in 
1 patient, myasthenic crisis treated in ICU in 2 patients, temporary 
palsy of right phrenic nerve in 1 patient, conversion to sternotomy 
due to intraoperative haemorrhage in 1 patient.  
 
Class of MG Before surgery / After surgery 
Class IIA 21 (50%) 35 (85%) 
Class IIB 12 (29%) 7 (17%) 
Class IIC 1 (2%) 0 (0%) 
Class III 8 (19%) 0 (0%) 
Class of MG before and after thymectomy according to Osserman 
classification The clinical state of muscle weakness according to 
Oosterhuis Index was assessed before and after thymectomy and 
was as follows: 
Class 0 – 0% / 19%
Class 1 – 14% / 28 %
Class 2 – 35% / 39%
Class 3 – 32% / 8%
Class 4 – 19% / 6%. 
The mean serum level of AChRAB before and after surgery was 
respectively 14,58 nmol/L and 12,34 nmol/L. P=0,2 (Wilcoxon 
signed-rank test). The medium dose of acetylcholinesterase inhib-
itors taken after surgery diminished statistically (p=0,53). There 
was no residual mass in mediastinum in follow – up chest CT In 
91% of patients. In 9% of patients there was negative contrast 
enhancing mass in mediastinum. 
Conclusions: Videothoracoscopic thymectomy is a safe surgical 
approach with potential to removal of the entire thymus gland.
Improvement in Osserman classification and Oosterhuis Index with 
lower level of AChRAB was noticed after surgery.
Unbiased neurological evaluation of this group of patients is diffi-
cult because of its heterogenity.
The effectivness of videothoracoscopic thymectomy requires ran-
domized controlled trials.
Disclosure: No significant relationships.
Keywords: improvement, videothoracoscopic thymectomy, Myas-
thenia gravis
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FUNCTIONAL MR IMAGING CAN IMPROVE CHARACTERIZA-
TION OF ANTERIOR MEDIASTINAL LESIONS.
Johan Coolen1, Frederik De Keyzer1, Eric Verbeken2, Christophe 
Deroose3, Johan Vansteenkiste4, Dirk De Ruysscher5, Walter De 
Wever1, Stephanie Peeters5, Christophe Dooms4, Paul De Leyn6, 
Kristiaan Nackaerts4, Johny Verschakelen1, Steven Dymarkowski1, 
Dirk Van Raemdonck6  
1University Hospitals Of Leuven, Radiology, Leuven/BEL-
GIUM, 2University Hospitals Of Leuven, Pathology, Leuven/BEL-
GIUM, 3University Hospitals Of Leuven, Nuclear Medicine, Leuven/
BELGIUM, 4University Hospitals Of Leuven, Pneumology, Leuven/
BELGIUM, 5University Hospitals Of Leuven, Radiation Oncology, 
Leuven/BELGIUM, 6University Hospitals Leuven, Thoracic Surgery, 
Leuven/BELGIUM
Purpose: Invasive surgical procedures (mediastinoscopy and 
-tomy) are at the moment the cornerstone of mediastinal oncologic 
staging, but can lead to patient discomfort and morbidity. In this 
study, we attempted to use a noninvasive MR imaging approach 
to differentiate benign from malignant anterior mediastinal lesions 
and at the same time attempt to provide an imaging-based preop-
erative evaluation of lesion resectability.
Materials and Methods: 60 consecutive patients (28 male, 32 
female), with a suspicious anterior mediastinal lesion on clinical or 
on imaging-based (CT, PET or EBUS) examinations, were included. 
Additional to the anatomical MRI sequences on a 3 Tesla scanner, 
both a DCE- and a DWI-acquisition were performed one day prior to 
surgery. All MR images were evaluated by visual inspection and by 
calculating the ADC values (mean) of the whole lesion and of the 
suspect zone (based on b1000 DWI and ADC map). Finally, the DCE 
curves were calculated and visually evaluated. Histological exam-
inations of operative specimens served as reference.
Results: A total of 27 benign and 33 malignant lesions were includ-
ed in this study. In total 51 patients were diagnosed correctly and 
9 incorrectly (4 FN and 5 FP) using a combination of DWI-MRI calcu-
lation (b1000 and ADC map) with DCE-MRI (sensitivity 87.9%, spec-
ificity 81.5% and accuracy 85.3%). Diagnosis based on the mean 
ADC calculated from the whole lesion was rather disappointing 
(sens. 63.6%, spec. 66.7% and acc. 65.0%) and showed an optimal 
threshold of 2x10-3mm²/s between benign and malignant lesions. 
However, the ADC calculation of the target zone evaluation alone 
was markedly better (sens. 78.8%, spec. 92.6% and acc. 85.0%) 
with an optimal cut-off value of 1.15x10-3mm²/s. Over all patients, 
a very good correlation was found between MR signs of local inva-
sion and surgical resectability (kappa 0.85, p<0.0001).
Conclusion: In the hard-to-image anterior mediastinal region, 
noninvasive imaging techniques (DWI- and DCE-MRI) might provide 
additional information for preoperative lesion characterization 
and assessment of lesion resectability. Volume and especially 
heterogeneity of the mediastinal lesion seem to preclude a simple 
whole-lesion delineation for diagnosis, but a combination of DWI 
and visual DCE-interpretation, or a targeted zone delineation allow 
better accuracies.
Clinical Relevance: MR imaging using DW- and DCE-MRI analysis 
could help to improve lesion characterization, can facilitate to 
assign the most appropriate biopsy site and might help to noninva-
sively predict lesions resectability prior to surgery.
Disclosure: No significant relationships.
Keywords: anterior mediastinal lesions, DWI and DCE-MRI, Func-
tional MR imaging
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A SURVEY OF CURRENT CLINICAL MANAGEMENT OF THY-
MIC CARCINOMAS AMONG ITMIG PHYSICIANS
Andreas Rimner1, Anna M. Litvak1, Frank C Detterbeck2, Pier Luigi 
Filosso3, Pam Bruce4, Usman Ahmad1, Arun Rajan5, Sanjay Popat6, 
James Huang1, Gregory J Riely1  
1Memorial Sloan Kettering Cancer Center, New York/UNITED 
STATES OF AMERICA, 2Yale University School Of Medicine, Depart-
ment Of Surgery, Division Of Thoracic Surgery, New Haven/UNITED 
STATES OF AMERICA,3University Of Torino, Torino/ITALY, 4Itmig, New 
Haven/UNITED STATES OF AMERICA, 5Thoracic And Gastrointestinal 
Oncology Branch, National Cancer Institute, Thoracic And Gastroin-
testinal Oncology, Bethesda/UNITED STATES OF AMERICA, 6Royal 
Marsden Hospital, London/UNITED KINGDOM
Introduction: Thymic carcinomas (TC) are rare malignancies of 
the thymus for which management recommendations are largely 
based on small retrospective series. In order to identify areas of 
agreement and variability in current clinical practice, we surveyed 
the membership of the International Thymic Malignancy Interest 
Group (ITMIG) with 12 vignettes of typical clinical scenarios.
Methods: A 16 question electronic survey was designed and ap-
proved by the members of the Thymic Carcinoma Working Group. 
Five-hundred and sixty-five ITMIG members were invited. Questions 
were directed at the diagnostic workup (n=1), definitive treatment 
approach (n=4), postoperative management (n=2), surgery op-
tions (n=2) chemotherapy options (n=1), and radiation therapy 
options (n=2).
Results: One-hundred and one ITMIG members replied to the 
questionnaire. Among the responders there were 60 surgeons, 18 
medical oncologists, 14 radiation oncologists and 11 physicians 
from other specialties. Responders had completed their specialty 
training ≤5 years ago in 14%, 6-20 years in 58%, and >20 years 
in 28%. North America (37%), Europe (43%) and Asia (20%) were 
all well represented. Approximately two thirds had a medium 
to high experience level in treating patients with thymic tumors 
(<6 patients per year =33%, 7 to 24 patients=49%, or >25 pa-
tients=17%). There was general agreement (>60%) regarding 1) 
need for adjuvant treatment (radiation therapy +/- chemotherapy) 
for stage III TC, 2) the use of definitive chemoradiation for the 
treatment of unresectable localized TC, 3) 3D conformal radiation 
therapy or intensity modulated radiation therapy for R1 resections, 
and 4) trimodality treatment of stage IVA TC with limited pleural 
metastasis with neoadjuvant chemotherapy followed by surgery 
and radiation. Areas of controversy included 1) need for histolog-
ical confirmation of TC prior to total thymectomy (core biopsy = 
38%, total thymectomy without biopsy = 54%), 2) role of adjuvant 
radiation therapy for stage II TC with more experienced physicians 
recommending adjuvant radiation therapy over observation, 3) 
role of surgical management of stage IVA TC with multiple pleural 
metastasis (>5) with surgeons more likely to recommend complete 
thymectomy with total pleurectomy as compared to medical on-
cologists (32% vs 0%), 4) type of chemotherapy for unresectable 
IVB disease with less experienced physicians recommending CAP 
therapy (<6 pts/yr=50%, 7-24pts/yr=35%, >25pt/yr=18%) and 5) 
treatment of patients with TC who present with cervical lymph node 
involvement with medical oncologists more likely to recommend 
chemotherapy only, surgeons more likely to recommend multimo-
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dality therapy with surgery, and radiation oncologists more likely to 
recommend chemoradiation.
Conclusions: The results of the questionnaire provide a descrip-
tion of the management of TC by ITMIG members. Although there 
was agreement in some areas, clinical practices vary widely based 
on experience level, location, and specialty. The areas of contro-
versy identified a clear need for collaborative research to identify 
optimal evaluation and treatment strategies.
Disclosure: No significant relationships.
Keyword: thymic carcinoma, survey, clinical management
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PURE RED CELL APLASIA ASSOCIATED WITH THYMOMA:  
A CASE SERIES
Elena Karampini1, Loïc Lang-Lazdunski2, Rohit Lal3  
1King’S College London, Guy’S Campus, Division Of Asthma, Aller-
gy And Lung Biology, London/UNITED KINGDOM, 2Guy’S And St 
Thomas’ Nhs Foundation Trust, Department Of Thoracic Surgery, 
London/UNITED KINGDOM,3Guy’S And St Thomas’ Nhs Foundation 
Trust, Cancer Centre, London/UNITED KINGDOM
Intoduction: Acquired pure red cell aplasia (PRCA) is a rare 
disorder of erythropoiesis, with preserved granulopoiesis and 
megakaryopoiesis. Less than 10% of patients with PRCA have an 
associated thymoma. The associated anaemia is thought to be due 
to an immune phenomenon and may respond to immunosuppres-
sive medication.
Method: We retrospectively reviewed the case notes of patients 
with PRCA and thymoma treated at our institution.
Results: Between 2004 and 2014, 5 patients were diagnosed 
with PRCA and a thymoma at our institution (3 male, 2 female). 
The median age at PRCA diagnosis was 55 years. Two patients 
were diagnosed with a thymoma in the course of investigations for 
PRCA, whereas three patients developed PRCA after the diagnosis 
of thymoma was made. Three patients underwent surgical excision 
of their thymoma (one required induction CAP chemotherapy and 
post-operative radiotherapy) and were given a Masaoka staging of 
I, IIb and III respectively. One patient underwent surgical exploration 
with resection abandoned due to the extent of the disease. She later 
went on to have Dotatate therapy. The fourth patient had extensive 
disease on imaging and proceeded to CAP chemotherapy with initial 
partial response to stable disease. Histological examination showed 
1 AB, 1 B1, 1 B2 and 2 B3 thymomas. All 5 patients had bone mar-
row examinations confirming PRCA. Marrow karyotype was normal in 
all cases. PRCA therapy varied with three patients receiving immuno-
suppressive therapy (one with cyclosporin only, one with cyclosporin 
and oral corticosteroids and one with oral corticosteroids and 
erythropoietin). One patient could not receive prolonged immuno-
suppressive therapy due to multiple other co-morbidities. The fifth 
patient’s anaemia resolved spontaneously. At last follow-up, only the 
patient who did not receive immunosuppressants remains transfu-
sion-dependent. No adverse effects were observed in the patients 
who received prolonged immunosuppression.
Conclusion: PRCA is one of the rare paraneoplastic syndromes 
associated with thymomas and should be considered in patients 
with anaemia in conjunction with a thymoma. Surgical resection 
aside, treatments to restore erythropoiesis usually involve pro-
longed immunosuppression with some patients remaining trans-
fusion-dependent despite the above. In view of their rarity and 
association with complex paraneoplastic syndromes, thymomas 
should ideally be managed by a multi-disciplinary team in a tertiary 
care setting.
Disclosure: No significant relationships.
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DISCOVERY OF THE ECTOPIC MEDIASTINAL FOCI OF THE 
THYMIC TISSUE IN THYMOMAS WITH THE USE OF THE NEW 
IMMUNOHISTOCHEMICAL REACTION
Monika Pasieka- Lis1, Juliusz Pankowski1, Marcin Zielinski2  
1Pulmonary Hospital, Department Of Pathology, Zakopane/PO-
LAND, 2Pulmonary Hospital, Department Of Thoracic Surgery, Zako-
pane/POLAND
Background: The incidence and clinical importance of the ecto-
pic foci of the thymic tissue in thymomas has never been studied, 
before. The aim of the study is to analyze the results of discovery 
of the ectopic mediastinal foci of the thymic tissue in thymomas 
with and without myasthenia gravis (MG) with use of the new immu-
nohistochemical (IHC) reaction. 
Material and Methods: The study group included patients op-
erated on for thymomas with and without MG in the period 2000-
2013. Extended transsternal or videothoracoscopic thymectomy 
was performed in all patients with removal of the adipose tissue of 
the neck, perithymic, right and left pericardiophrenic, aorta-caval 
and aorta-pulmonary window areas. The mediastinal fatty tissue 
was subsequently stained with Hematoxillin-eosin (HE) and studied 
with light microscopy. The results were positive in case of discov-
ery of the Hassall bodies. Subsequenty IHC was performed with 
use of the Anti-Pan Keratin (CK-PAN) (AE1/AE3/PCK26) Primary 
Antibody (Isotype IgG1) ( Ventana Medical Systems) including the 
mousy monoclonal antibodies directed against the epitope present 
on the human epithelial cytokeratins. Differences in proportion of 
patients with Hassall bodies and IHC with CK-PAN between patients 
with and without MG were assessed using two-sample test of pro-
portions. Differences in ectopic foci incidence were checked by 
chi2test or Fisher exact test if needed. 
Results: There were 43 patients, 34 of them with MG-associated 
thymomas and 9 with thymomas without MG. The Hassall bodies 
were found in 1/9 (11.1%) patients with thymoma without MG and 
in 15/34 (44.1%) with thymomas with MG (p=0.069). The IHC with 
CK-PAN was positive in 4/9 (44.4%) patients with thymoma without 
MG and in 22/34 (64.7%) with thymomas with MG (p=0.268). 
The highest incidence of the ectopic foci was found in the perithy-
mic and the aorta-pulmonary window(okienko) areas (60.5% and 
53.6% for IHC, and 58.3% and 27.0% for IHC, respectively) but they 
were also found in all other areas of the anterior and middle medi-
astinum. The incidence of ectopic foci in different areas of the fatty 
tissue of the neck and mediastinum were not different between 
patients with and without MG. The incidence of the ectopic thymic 
foci was not influenced by age, sex, histology of the thymus, the 
WHO type of thymoma and the Massaoka stage.
Conclusions: Immunohistochemistry proved to be useful in discov-
ery of the ectopic mediastinal thymic foci in thymomas.
The incidence of the ectopic foci was higher in case of thymomas 
associated with MG vs thymomas without MG, however the differ-
ences were not statistically significant.
Our preliminary results support the use of extended thymectomy 
for thymomas with and without MG although further studies with 
larger number of patients are necessary to confirm these results.
Disclosure: No significant relationships.
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ITMIG DEFINITION OF MEDIASTINAL COMPARTMENTS 
Brett W. Carter1, Noriyuki Tomiyama2, Faiz Bhora3, Melissa L. Ro-
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ri-Kansas City, Saint Luke’S Hospital Of Kansas City, Radiology, 
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Division of the mediastinum into compartments is used to help 
narrow the differential diagnosis of newly detected mediastinal 
masses, to assist in planning biopsy and surgical procedures, 
and to facilitate communication among clinicians of multiple 
disciplines. Several traditional mediastinal division schemes 
exist based upon arbitrary landmarks on the lateral chest radio-
graph. We describe a modern, computed tomography (CT) -based 
mediastinal division scheme, which has been accepted by the 
International Thymic Malignancy Interest Group as a new stan-
dard. This clinical classification defines a prevascular (anterior), 
a visceral (middle) and a paravertebral (posterior) compartment, 
with anatomic boundaries defined clearly by CT. We anticipate 
that this system will improve tumor localization, help generate 
a focused differential diagnosis and assist in tailoring biopsy 
and treatment plans. In addition, this system should facilitate 
communication among surgeons, oncologists, radiologists, and 
pathologists worldwide, with the added benefit of ultimately help-
ing to create meaningful prevalence studies across institutions.
 
 
Disclosure: No significant relationships.
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D2-40: A GOOD IMMUNOHISTOCHEMICAL MARKER FOR B2 
THYMOMAS
Malgorzata Szolkowska1, Renata Langfort1, Sebastian Winiarski2, 
Piotr Rudzinski2, Dorota Giedronowicz1, Ewa Szczepulska-Wojcik1, 
Beata Maksymiuk1, Tadeusz Orlowski2  
1National Tuberculosis And Lung Diseases Research Institute, Pa-
thology Dpt., Warsaw/POLAND, 2National Tuberculosis And Lung 
Diseases Research Institute, Clinic Of Surgery, Warsaw/POLAND
Background: Clinical stage, resectability and histological sub-
type of thymoma are the most important prognostic factors in the 
disease. Due to great heterogeneity of morphology in routine H&E 
staning, proper classifying of thymomas can be challenging. Im-
munohistochemical markers for cortical or medullar epithelial cells 
could be helpful. D2-40 is an antibody, that recognizes podoplanin, 
transmembrane glycoprotein found in various normal and neoplas-
tic cells including lymphatic endothelium, mesothelial cells, stromal 
reticular cells and follicular dendritic cells of lymphoid tissue. The 
antibody is widely used by pathologists in diagnostics of mesotheli-
oma, lymphatic-derived tumors or lymphatic invasion by neoplastic 
cells. Some authors report relationship between D2-40 expression 
and stage of thymoma or poor clinical outcome of the disease, but 
no correlation with histological subtype. 
Materials and Method: 59 thymic epithelial tumors (53 thymo-
mas and 5 thymic carcinomas, TC) were analyzed for expression 
of podoplanin using of D2-40 antibody. The extent and the type of 
reaction (membraneous or cytoplasmic) were assessed. Lymphatic 
vessels, remnants of normal thymus or lymphoid follicles in the 
stroma represented an internal positive control of reaction. The 
histological subtype of tumor was established according to WHO 
classification (2004) and the stage of thymomas under Masaoka 
staging system. Results Group of thymomas encompassed 3 type 
A, 12 AB, 6 B1, 11 B2, 2 B3, 2 micronodular, 1 metaplastic and 17 
combined thymomas including B2B3 (11), B1B2 (4) and B1B2B3 (1) 
and AB/micronodular type (1). Three of 5 TCs revealed squamous 
and 1 neuroendocrine differentiation. One carcinoma was not spec-
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ified. Positive anti-D2-40 reaction was observed in 1 (33%) type A 
thymoma, 3 (25%) AB, 2 (40%) B1, 12 (100%) B2, 9 (82%) B2B3, 
3 (75%) B1B2, 1 (100%) B1B2B3 and 1 (100%) metaplastic type. 
Neither pure B3 and micronodular thymomas nor TCs revealed 
expression of podoplanin. B2 (pure or combined) presented almost 
exclusively membranous type of reaction unlike with other types of 
tumors (A, AB, B1 and metaplastic). Mean area of tumor positive 
for D2-40 was: <1% for type A and AB, 10.2% for B1, 16.67% for 
B2, 24.64% for B2B3, 15.75% for B1B2, 20% for B1B2B3 and 2% 
for metaplastic type. There were 6 tumors in the 1st, 36 in the 
2nd, 6 in 3rd and 4 in 4th stage. The stage of disease could not be 
determined in 7 tumors. Four tumors (67%) of stage 1, 19 (53%) 
of stage 2, 4 (67%) of stage 3 and 4 (100%) of stage 4 expressed 
podoplanin. Mean area of tumor that disclosed reactivity was: 
18.33%, 9.61%, 15.33% and 17.75% respectively. Reaction in tu-
mor cells had variable intensity, but usually weaker than in control 
tissues. 
Discussion: Results of our study revealed that positive, membra-
nous reaction with D2-40 antibody in neoplastic cells that involves 
over 10% of area of tumor strongly suggests B2 component. 
Either cytoplasmic reaction or reactivity in lymphoid stroma is not 
diagnostic. There were no relationship between the reactivity and 
tumor stage.
Disclosure: No significant relationships.
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POSITRON EMISSION TOMOGRAPHY IN THYMIC LESIONS’ 
SURGERY. A PROSPECTIVE STUDY. 
 
Sotirios Dimitrios Moraitis1, Evangellia Skoura2, Kostantinos 
Kanakakis1, Ioannis Gkiozos3, Dimitrios Moraitis4, Kostantinos N. 
Syrigos3, Theodore Liakakos5  
1Naval And Veterans Hospital Of Athens, Cardiothoracic Surgery 
Dpt., Athens/GREECE, 2Evangelismos Gen. Hospital, Nuclear Med-
icine Dpt., Athens/GREECE, 3Sotiria Gen.Hospital, Athens Univer-
sity Medical School, Oncology Unit, Athens/GREECE, 4Naval And 
Veterans Hospital Of Athens, Athens/GREECE, 5Attikon University 
Hospital, Athens University Medical School, Surgical Department, 
Athens/GREECE
Aim: To evaluate the utilization of positron emission tomography 
(PET) scan with fluorine-18 fluorodeoxyglucose (FDG) in the selec-
tion of the surgical approach for thymic lesions.
Material and Methods: Seventeen consecutive patients with 
thymic pathology, underwent PET-FDG after being evaluated by 
computed tomography (CT), since 2011. The Standard Uptake Val-
ue (SUV) max of the lesion, as well as the SUV of the mediastinum, 
were estimated. The ratio SUVmax Lesion/Mediastinum was the 
caliber for selecting thoracoscopic thymectomy (TT) or thymecto-
my via median sternotomy (TMS), as the therapeutic procedure. If 
the ratio SUVmax L/M < 1, thoracocscopic thymectomy was pref-
erable. If the ratio was, 1 < SUVmax L/M < 2, the selection was 
depended on the lesion’s dimensions (TT was preferred for lesions 
< 4 cm). If the ratio was SUVmax L/M > 2, a median sternotomy 
was the approach of choice.
Results: There were 12 male and 5 female patients, with a mean 
age of 41.1 y.o. In 10 patients the ratio SUVmax L/M showed up 
> 1, while in 4 patients was higher than 2. The histopathology re-
vealed 5 thymomas, 2 thymolipomas, 5 true thymic hyperplasias, 
1 non seminomatous tumour, 1 silicone indused lemphadenopathy 
while 1 patient is waiting for TT and another one (type C thymoma 
by fine needle biopsy), for TMS. The mean SUVmax for thymomas 
was 3.02+-1.67, for thymolipomas was 1.48+-0.26, for true thymic 
hyperplasias was 1.82+-0.42, while the non seminomatous’ tumour 
SUVmax was 12.4. There have been performed 4 TTs, 1 Trans-
cervical approach and 9 TMSs. R0 resection was achieved in all 
14 patients, have undergone operation, so far. All patients had an 
uneventful postoperative course and the mean duration of hospital 
stay was 4 days for TTs and 7 days for TMSs.
Conclusions: There is no imaging modality sufficient by itself to 
identify the nature of thymic lesions. The intensity of FDG uptake is 
useful for predicting the grade of malignancy, and high FDG uptake 
may reflect the invasiveness of the malignant nature in thymic ep-
ithelial tumors. The creation of a scale of “metabolic biopsy” with 
the use of the ratio SUVmax L/M, will allow the use of TT to a larg-
er patient population, following of course, the surgical oncology 
guidelines for the removal of thymic lesions.
Disclosure: No significant relationships.
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EBV-ASSOCIATED THYMIC LYMPHOEPITHELIOMA-LIKE CAR-
CINOMA (LELC) : A CASE SERIES .  
Haim Biran1, Einav Nili Gal-Yam2, Marina Perelman3, Iris Kventsel4, 
Simona Ben-Haim5  
1Sheba Medical Center, Thoracic Oncology Oncology Division, Ra-
mat Gan/ISRAEL, 2Sheba Medical Center, Cancer Research Center, 
Ramat Gan/ISRAEL, 3Sheba Medical Center, Institute Of Pathology, 
Ramat Gan/ISRAEL,4Sheba Medical Center, Pediatric Hemato-Oncol-
ogy, Ramat Gan/ISRAEL, 5Sheba Medical Center, Nuclear Medicine, 
Ramat Gan/ISRAEL
Background: Thymic carcinoma (TC) consists of only 1% of all 
thymic neoplasms , by themselves uncommon. A few distinctive TC 
variants are known, one of them is LELC, occurring in young adults. 
Association of the latter entity with EBV has been described.
Methods: Tumoral EBV expression, assayed by in-situ hybridization 
(ISH) in 1 case (see picture below); by immunohistochemistry (IHC) 
in two . IHC included MNF116, CD5, CD3, TdT, CD1A , c-Kit and 
Ki67. Presence of somatostatin receptors was evaluated by PET 
Ga68 DOTANOC-octreotate scan.
Results: During the years 2011-2013 we have treated three young 
(16-21 years old) male patients with similar clinical attributes. All 
presented with an advanced disease: Masaoka-Koga Stage Iva/b 
and high tissue Ki67 proliferation index. All responded to 1st-line 
platinum/etoposide, or CAP (doxorubicin combination) but relapsed 
thereafter. Two were given radiation to the primary mediastinal 
tumor. Further chemotherapy included CHOP (1 case) and capecit-
abine combined with either cisplatin, gemcitabine or irinotecan and 
oxaliplatin in different cases. Sunitinib and everolimus yielded no 
benefit. Two patients, having positive octreotate scans, were treat-
ed by octreotide depot and enjoyed a clinical benefit and objective 
stability. Two patients received peptide-receptor radionuclide (Lute-
cium 177) therapy (PRRT) conferring partial response in one case. 
Two patients have expired 18 and 25 months from diagnosis, while 
one is surviving, with disease, 30+ months.
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Conclusion: Despite the dismal prognosis in thymic carcinoma 
at large and in LELC patients as well, our experience indicates 
that meaningful palliation and apparent survival prolongation are 
feasible. Biologic tumor targets such as SSTR, notable in this small 
series. and potential others should be explored for personalized 
therapy in the context of an orphan disease. The underlying role of 
EBV is currently unknown; however, a Phase I trial in nasopharyn-
geal carcinoma with the related vaccinia Ankara has been reported 
(Hui EP et al, 2013). Further collaborative research effort is war-
ranted.
Disclosure: No significant relationships.
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MEDULLARY APLASIA: A SEVERE CONDITION ASSOCIATED 
TO THYMIC EPITHELIAL TUMOR (TET)
Stefano De Falco, Claudia Von Arx, Carlo Buonerba, Margaret Otta-
viano, Piera Federico, Filomena Calabrese, Lucia Nappi, Pasquale 
Rescigno, Vincenzo Damiano, Giovannella Palmieri  
Aou Federico Ii Rare Tumors Referal Center Campania Region, On-
cology, Naples/ITALY
Background: Thymic epithelial tumors constitute a wide category 
of rare neoplasia with a large spectrum of pathologic characteris-
tics and clinical presentations. Hematological complications such 
as pure red cell aplasia (PRCA) and aplastic anemia are document-
ed in about 15% of patients with TET. Amegakaryocytic thrombo-
cytopenia is not a well studied paraneoplastic syndrome of thymic 
cancers, owing to its rarety.
Materials and Methods: We report four cases of TET compli-
cated with PRCA and amegakaryocytic purpura and consequent 
complete bone marrow failure observed at “Centro di Riferimento 
Tumori Rari” in Naples.
Results: Study Population is composed by 2 women and 2 men; 
all the patients had Thymoma B2 or B3 sec. WHO 2004, three 
patients with stadium IVB sec Masaoka and one IVA. They were 
diagnosed as PRCA and amegakaryocytic thrombocytopenia during 
treatment for primitive tumor at about 3 years from the diagnosis 
of TET. They had no benefit from treatment with high-dose cor-
ticosteroids and Immunoglobulins. Several immunosuppressive 
therapies were performed after the diagnosis of complete med-
ullary aplasia: all the patients were treated with cyclosporine A; 
One patient with Tacrolimus; One patient with Alemtuzumab and 
plasmapheresis. Neverthless three patients died for severe infec-
tions, particularly: one died for respiratory infections, one for viral 
myocarditis and one for viral encephalitis; the last patient is still in 
course of treatment.
Conclusions: PRCA, amegakaryocytic thrombocytopenia and 
medullary aplasia are life-threatening conditions that influence 
significantly prognosis of patients affected by TET, and require 
intensive multidisciplinary approach for the management of associ-
ated hemorrhagic and infective complications.
Disclosure: No significant relationships.
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EVALUATION OF RESECTABILITY OF THYMOMAS VIA CINE MRI
Hendrik Dax, Lukas Kirzinger, Rosemary Kollanur, Berthold Schalke  
University Hospital Of The University Of Regensburg, Neurology, 
Regensburg/GERMANY
Thymomas are slow-growing tumors of the anterior mediastinum 
with the highest prevalence at the age of 40-60 years. There is a 
strong association with paraneoplastic syndroms especially the 
neuromuscular junction disorder myasthenia gravis not uncommon-
ly producing the first clinical symptoms with weakness of voluntary 
muscles. When the suspicion of a thymoma arises on a CT scan the 
next diagnostic step consists of obtaining a tissue sample either 
by complete surgical excision or biopsy. A precise histopathologic 
examination of the specimen establishes the diagnosis of thymoma 
and the tumor is staged according to the widely accepted Massao-
ka staging system. The latter classifies thymomas according to the 
extent of tumor mass and the presence of invasion into adjacent 
structures or the occurrence of metastases. While tumor stage at 
the time of diagnosis comprises an independent predictor of long-
term survival, resectability of tumor mass has also been shown to 
be crucial for the prognosis of the patient. Thymomas that extend 
to adjacent structures like the pericard, the pleura or big vessels 
comprise a special challenge for surgeons as they potentially 
face an unresectable tumor that has already invaded deeply into 
adjacent organs or vessels. At the interface between tumor and 
these organs CT scan imaging of the thorax often does not provide 
enough information upon which a valid statement can be made 
whether a complete resection will be possible or not. In these cas-
es we propose the application of a novel imaging technique. Cine 
MRI is a method where MRI imagines are obtained ECG triggered, 
finally allowing for the assessment of moving organs. While the 
patient holds her/his breath a set of MRI imagines is acquired over 
the period of several cardiac circles. Each cardiac circle is divided 
into 20 segments or frames. The information of several imagines 
of the same frame is fused creating a sharply delineated clear 
result for each frame. In the end, the sequence of these individual 
frames can be displayed like a movie (cine). These movies can be 
very helpful specifically in the assessment of the interface between 
thymoma and mediastinal organs like the heart or big vessels. A 
tumor that seems so slide smoothly along the surface of the peri-
cardium during the cardiac circle is likely to be easily accessible 
for complete resection. In contrast to this, a different approach is 
warranted for patients where the tumor seems to adhere to cardial 
tissue on Cine MRI imaging. In this case neoadjuvant therapy to first 
reduce tumor size in order to increase the chance of a complete 
resection might be the better option.
Disclosure: No significant relationships.
Keywords: Therapy, Resectability, Thymoma, Cine MRI
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RESULTS OF MULTIMODALITY TREATMENT FOR THYMIC 
CARCINOMA AND THE CURRENT CHALLENGE
Masayoshi Inoue, Yasushi Shintani, Soichiro Funaki, Tomohiro 
Kawamura, Masato Minami, Meinoshin Okumura  
Osaka University Graduate School Of Medicine, Department Of 
General Thoracic Surgery, Suita, Osaka/JAPAN
Background: Thymic carcinoma is frequently found as a locally 
advanced disease. Complete resection is practically recommended 
as a radical treatment, if possible. Otherwise, chemotherapy and 
irradiation are indicated for unresectable cases, while there is no 
standard treatment. We have challenged aggressive multimodality 
strategy including preoperative chemoradiation followed by extend-
ed resection with neighboring organs, occasionally using cardiopul-
monary bypass (CPB). 
Objective and Methods: We retrospectively analyzed 45 thymic 
carcinoma patients who underwent surgical intervention in our insti-
tute to clarify the outcome and the efficacy of the multimodality 
treatment for thymic carcinoma. Stage was classified as Masaoka 
I in 2, II in 1, III in 21, IVa in 6, and IVb in 15 patients. Histological 
diagnosis was reported as squamous cell carcinoma in 25, neuro-
endocrine carcinoma in 10, and others in 10 patients. Statistical 
analyses for survival were performed using Kaplan-Meier method 
and log-rank test. 
Results: The 5-year and 10-year overall survival (OS) rates 
were 59.9% and 40.4%, respectively. A complete resection was 
achieved in 27 patients and the 5-year OS was 79.2%, which was 
significantly better as compared to 36.2% for the patients’ group 
with an incomplete resection (p<0.01, Fig.1). Preoperative therapy 
was indicated in 15 patients; 10 chemoradiation and 5 chemothera-
py alone in 5. The complete resection rate was 60% after preoper-
ative therapy. The 5-year OS was 84.6% and 49.6% in patients with 
and without preoperative therapy, respectively, while there was 
no significant difference. According to the histology, patients with 
squamous cell carcinoma showed a tendency to be better outcome 
and the 5-year OS was 71.4%, though it was 40.6% in patients with 
non-squamous cell carcinoma (p=0.08). Recently, we encountered 
two patients who underwent a complete resection using CPB due 
to the direct invasion into the aorta after preoperative chemoradia-
tion therapy (Fig.2). These patients survive without recurrence for 
52 and 14 months. 
Conclusion: Multimodality treatment for advanced thymic 
carcinoma is feasible. Recent progress of safe extended sur-
gery in addition to effective chemotherapy and irradiation 
may contribute to the improvement of the outcome, since 
only a complete resection is an independent prognostic fac-
tor and the local control is essential in thymic carcinoma.
 
Disclosure: No significant relationships.
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PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA
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1Stanford University School Of Medicine, Department Of Medicine, 
Division Of Oncology, Palo Alto/UNITED STATES OF AMERICA, 2Uni-
versity Of California Davis School Of Medicine, Department Of 
Internal Medicine, Division Of Hematology/Oncology, Sacramento/
UNITED STATES OF AMERICA, 3Stanford University School Of Medi-
cine, Department Of Radiation Oncology, Palo Alto/UNITED STATES 
OF AMERICA, 4Ukiah Valley Rural Health Center, Department Of 
Medicine, Division Of Oncology, Ukiah/UNITED STATES OF AMERI-
CA, 5Stanford University School Of Medicine, Department Of Cardio-
thoracic Surgery, Palo Alto/UNITED STATES OF AMERICA
Introduction: Pruritus in malignancy is most strongly associated 
with Hodgkin’s disease (HD), afflicting 30% of patients and acting 
as a paraneoplastic symptom for up to 5 years prior to diagnosis. 
Here, we report pruritus as a paraneoplastic symptom for two 
patients with thymoma.
Case 1 is a 36 year-old woman who presented with generalized 
pruritus without rash during her second pregnancy and her symp-
toms did not resolve after delivery. A trial with antihistamines and 
topical steroids did not help. She had a normal physical exam 
without lymphadenopathy or hepatosplenomegaly; no evidence 
of thyroid disease; normal complete blood count and differential 
(CBC+diff) and kidney and liver function; normal lactate dehydroge-
nase and erythrocyte sedimentation rate; negative hepatitis panel; 
and a right upper quadrant ultrasound without cholelithiasis or 
cholestasis. When the patient had a chest x-ray (CXR) >14 months 
from the onset of pruritus, it showed an anterior mediastinal mass. 
CT chest demonstrated a 5.1 cm mediastinal mass that abutted 
but did not appear to invade the great vessels. Chest MRI revealed 
no fat plane between the mediastinal mass and pericardium, clini-
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cally concerning for Masaoka-Koga stage III disease. A CT-guided 
fine needle aspiration was nondiagnostic. Because of the concern 
for HD given the pruritus, a repeat core biopsy was performed and 
was also nondiagnostic but immunohistochemistry staining for HD 
was negative. The patient underwent 2 cycles of cisplatin, cyclo-
phosphamide, and doxorubicin (CAP) chemotherapy for presumed 
thymoma. Her pruritus resolved 3 days after her first cycle and 
did not return. She had significant decrease in the size of the me-
diastinal mass and after one more cycle of CAP, she had a median 
sternotomy and complete thymectomy. Pathology demonstrated 
a Masaoka-Koga stage II WHO type B2 thymoma, without a clearly 
defined capsule and microscopic foci of tumor in the mediastinal 
fat, but margins were negative. The patient did not receive post-op-
erative radiation given the R0 resection.
Case 2 is a 60 year-old woman who presented with 12 months 
of intermittent pruritus without rash in the upper extremities and 
back. A physical exam was normal and she had a normal CBC+diff 
except for mild leukocytosis and normal kidney function. She had 
a screening CXR for work that showed a large right anterior me-
diastinal mass. CT chest revealed an 11.8 cm well-circumscribed 
mediastinal mass. A CT-guided core biopsy confirmed thymoma. 
Clinically, she had a Masaoka-Koga stage I or II thymoma and the 
decision was made to forego neoadjuvant chemotherapy. She had 
a median sternotomy, complete thymectomy, and wedge excision 
of a right upper lobe (RUL) lung nodule. Pathology demonstrated 
a fully encapsulated Masaoka-Koga stage I WHO type AB thymo-
ma and the wedge lung biopsy showed an organizing pneumonia 
pattern. The pruritus resolved promptly after surgery and did not 
return.
Conclusions: We report, to our knowledge, the first cases of pru-
ritus as a paraneoplastic symptom of thymoma. Pruritus is more 
frequently associated with another anterior mediastinal malignancy, 
HD. In our cases, pruritus was present for >12 months prior to 
diagnosis and resolved promptly after treatment.
Disclosure: No significant relationships.
Keyword: pruritus, paraneoplastic, thymoma
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PELVIC METASTASIS FROM THYMIC CARCINOMA:  
A CASE REPORT
Eric Dansin1, Ecatarina Surmei-Pintilie2, Fabrice Narducci3, Isabelle 
Farré4, Géraldine Lauridant1, Hélène Kolesnikov-Gauthier5, Thomas 
Boulanger6, Henri Porte2  
1Centre Oscar Lambret, Medical Oncology, Lille/FRANCE, 2Chru 
Hopital Calmette, Thoracic Surgery, Lille/FRANCE, 3Centre Oscar 
Lambret, Surgical Oncology, Lille/FRANCE, 4Centre Oscar Lambret, 
Bio-Pathology, Lille/FRANCE, 5Centre Oscar Lambret, Nuclear 
Départment, Lille/FRANCE, 6Centre Oscar Lambret, Imaging Depart-
ment, Lille/FRANCE
Introduction: Thymic epithelial tumors are rare and more often 
localized. Metastatic sites of thymic carcinoma (Masaoka-Koga 
stage IVb) included mainly lung, liver and brain.
Case report: We report a 64 year-old woman’s case with an initial 
diagnosis of thymoma B3 treated by pre-operative chemo-radio-
therapy followed by complete resection. Six years later parietal 
and pleural tumors were detected by CT scan and [18F]FDG-PET/
CT. These lesions were resected and were confirmed as metastasis 
of mixed thymoma B3 and thymic carcinoma. Eleven years after 
initial diagnosis of thymoma a pelvic mass was detected by [18F]
FDG-PET/CT (SUVmax 8.4) and confirmed by MRI . The patient was 
asymptomatic. A laparotomy confirmed an isolated peritoneal 60 
mm tumoral mass localized on left part of the douglas’ pouch. The 
lesion was completely resected. Pathological analysis concluded to 
a metastasis of the previously diagnosed thymic carcinoma.
Discussion: Peritoneal and/or ovarian metastasis from thymic 
malignancies are very rare. Four cases had been reported in the 
literature. There were observed with different thymic histological 
subtype (carcinoma, B1, neuroendocrine) and were always associ-
ated with loco-regional extension and/or distant metastasis.
Conclusion: To our knowledge this is the first report of an isolated 
pelvic metastasis from thymic carcinoma. Efficacy of [18F]FDG-
PET/CT is well established in patients with thymic epithelial tumors 
to detect and localize mediastinal recurrence. Our case report 
emphasizes also the utility of [18F]FDG-PET/CT for metastasis 
detection and long term follow-up.
Figures: Baseline thoracic CT scan (2002), [18F]FDG-PET/CT 
(2013), Pelvic MRI (2013), Histological features of the pelvic me-
tastasis
Disclosure: No significant relationships.
Keywords: Thymic carcinoma, positron emission tomography, 
pelvic metastasis, Thymoma
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THYMOMA AND THYMIC CARCINOMA: A MULTIVARIATE 
ANALYSIS OF PROGNOSTIC FACTORS IN 220 PATIENTS
Mkrtich Mkrtchyan1, Georgios Stamatis2, Stefan Welter2, Danjouma 
Cheufou2  
1Yerevan State Medical University, Armenia, Surb Grigor Lusavorich 
” Medical Center, Department Of Thoracic Surgery, Yerevan/AR-
MENIA, 2Ruhrlandklinik Essen, Germany, Department Of Thoracic 
Surgery, Essen/GERMANY
Objective: The diversity of the biological, oncological and his-
tological features of thymoma and thymic carcinoma generate 
difficulties for researchers to establish main prognostic factors. 
Retrospective analysis of 220 patients with thymoma and thymic 
carcinoma was conducted at the Department of Thoracic Surgery, 
Ruhrlandklinik Essen, Germany from January 1998 to July 2013. 
The goal of the analysis was to determine prognostic factors in 
this patient population. Thymomas and thymic carcinomas are rare 
malignant tumors and have a low prevalence.
Methods: 220 patients (137 male and 83 female) diagnosed 
with thymoma and thymic carcinoma and subjected to surgical 
treatment were reviewed retrospectively for the 15 year period. 
The mean age of the patients was 56.37 ± 15.06. Influences of 
age, Masaoka-Koga stage, WHO histological type, completeness 
of resection and Myasthenia Gravis were analyzed. The surgical 
treatment included sternotomy (191), thoracotomy (12), VATS (13) 
and sternotomy+thoracotomy (4). Total tumor removal included R0 
resections (85%), microscopic incomplete resections (R1) (12.7%) 
and macroscopically incomplete resections (R2) (2.3%). Myasthe-
nia Gravis was observed in 18.2% of patients.
Results: The 5-year overall survival rate (OS) after complete resec-
tion was 92.5% and was significantly higher than after incomplete 
resection (78.5% (R1) and 60% (R2); p <0.05). The 5-years OS of 
early Masaoka-Koga stage I (92.7%) and II (89.8%) were significant-
ly higher than advanced stages III (61.4%) and IV (40.0%), p<0.05). 
WHO type A (23.6%), AB (16.8%) and B1 (12.7%) tumors have 
better prognosis than other types B2 (10%); B3 (10%), C (26.9%). 
Survival rate in WHO (A, AB, B1 ) was 93.2% in WHO (B2, B3) 
51.3.% and in WHO (C) the rate was 18.9% (P<0.05). Age, Myasthe-
nia Gravis and type of surgical treatment didn’t have statistically 
significant influence on 5-year survival rate.
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Conclusions. From the 5 variables analyzed in the present study 
only Masaoka-Koga stage, WHO histological type and complete-
ness of resection proved to be significant prognostic factors that 
affect the 5-year survival rate.
Disclosure: No significant relationships.
Keyword: Thymoma, thymic carcinoma, prognostic factors
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PRIMARY MEDIASTINAL MALIGNANT LYMPHOMA.  
A CLINICOPATHOLOGICAL STUDY.
Jun Nakajima, Keita Nakao, Tomohiro Murakawa, Masaki Anraku, 
Jun-Ichi Nitadori, Kazuhiro Nagayama, Chihiro Konoeda  
The University Of Tokyo Graduate School Of Medicine, Department 
Of Thoracic Surgery, Tokyo/JAPAN
Background: Majority of the primary mediastnal malignant lym-
phoma is aising from the thymic region. The thymus is likely to be 
involved by the large B cell lymphoma (PBML) or the classical Hod-
gkin lymphoma (cHL). To determine therapeutic strategy, we need 
the correct diagnosis of the subtype of the malignant lymphoma. 
Materials and Methods: We retrospectively collected medical 
records of the patients with the malignant lymphoma of the anteri-
or mediastinum from 1998 to 2014 in our hospital. 
Results: Twenty-one patients were eligible for the diagnostic crite-
ria with the age ranging from 19 to 72 year-old. Eleven men and 10 
women were included. The pathological diagnoses of the subtype 
were PBML in 10 patients, the nodular sclerosis type of cHL in 8 
patients, the T-lymphoblastic leukemia / lymphoma in 1 patient, the 
follicular lymphoma in 1 patient, and the grey-zone lymphoma in 1 
patient. Mean diameter of the mediastinal tumor was 103 mm and 
102 mm in PBML and cHL patients, respectively. One patient with 
cHL had suffered from B-symptoms. Mean values of serum LDH, 
CRP, sIL2-Receptor of PBML patients were 325 U/L, 3.1 mg/dL and 
2002 U/L, respectively. Those of cHL patients were 225 U/L, 2.1 
mg/dL, and 948 U/L, respectively. Serum LDH of PBML patients 
were significantly higher than that of cHL patients (p=0.008). Six 
patients were pathologically diagnosed with percutaneous needle 
biopsy. We performed surgical resection of the tumor on other 
patients to determine the final diagnosis. 
Conclusion: We suggest that serum titer of LDH might help us 
distinguish PBML from cHL. The final diagnosis was determined 
with the pathological examination of the biopsied specimen which 
was often retrieved by surgical resection.
Disclosure: No significant relationships.
Keywords: classical Hodgkin lymphoma, Large B cell lymphoma, 
Mediastinum, malignant lymphoma
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RADIOGRAPHIC ASSESSMENT OF TREATMENT RESPONSE 
OF THYMIC NEOPLASMS USING MODIFIED RECIST CRITERIA
Marcelo F Benveniste1, Robert J Korst2, Arun Rajan3, Frank C Det-
terbeck4, Brett W Carter1, Edith M Marom1  
1The University Of Texas Md Anderson Cancer Center, Diagnostic 
Radiology, Houston/UNITED STATES OF AMERICA, 2The Valley Hos-
pital, Division Of Thoracic Surgery, Ridgewood/UNITED STATES OF 
AMERICA, 3Thoracic And Gastrointestinal Oncology Branch, National 
Cancer Institute, Thoracic And Gastrointestinal Oncology, Bethesda/
UNITED STATES OF AMERICA, 4Yale University School Of Medicine, 
Department Of Surgery, Division Of Thoracic Surgery, New Haven/
UNITED STATES OF AMERICA
Imaging evaluation is essential in diagnosis, staging and assess-
ment of treatment response in thymic epithelial malignancies and 
computed tomography is the imaging modality of choice for eval-
uating thymoma. There is variability in the medical community in 
how these tumors are measured for treatment response. Accurate 
measurement of tumor response to treatment is important not 
only for assessment if therapy is to be continued for the individual 
patient, but also for drug trials in which new chemotherapy reg-
imens are assessed for their effectiveness. In this presentation 
we will emphasize how advanced disease should be measured 
to provide an accurate and universal measurement method that 
can be consistently performed minimizing intra- and interobserv-
er variability in routine film interpretation and in clinical trials.
Disclosure: No significant relationships.
Keyword: Thymic Neoplasm, ITMIG, response measurement
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IMAGING APPROACH TO ANTERIOR MEDIASTINAL MASSES
Brett W. Carter1, Meinoshin Okumura2, Marcelo F Benveniste1, Frank 
C Detterbeck3, Edith M Marom1  
1The University Of Texas Md Anderson Cancer Center, Diagnostic 
Radiology, Houston/UNITED STATES OF AMERICA, 2Osaka University 
Graduate School Of Medicine, Department Of General Thoracic 
Surgery, Osaka/JAPAN,3Yale University School Of Medicine, Depart-
ment Of Surgery, Division Of Thoracic Surgery, New Haven/UNITED 
STATES OF AMERICA
Mediastinal masses are relatively uncommon, yet include a large 
variety of entities. A structured approach will be presented to 
facilitate evaluation of patients with anterior mediastinal tumors. 
The approach will focus first on the more common tumors and 
on imaging features that strongly suggest a particular diagno-
sis. Some lesions can be reliably identified by imaging alone, 
including substernal goiters, benign teratoma, and benign cysts. 
However, many anterior mediastinal tumors exhibit suggestive 
but inconclusive imaging features; when the imaging correlates 
with the typical clinical features a presumptive diagnosis can 
be quite reliable. This underscores the need for a discussion 
between the clinician and the radiologist when evaluating most 
anterior mediastinal tumors. The suggested approach therefore 
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is to initially rule in or out those lesions that can be reliably iden-
tified purely on the basis of characteristic imaging features. Less 
conclusive imaging features should be correlated with specific 
clinical features; in many cases this will strongly suggest a par-
ticular diagnosis and a further evaluative or treatment strategy.
 
Disclosure: No significant relationships.
Keyword: Mediastinum; Anterior; Imaging; CT; MRI
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MYASTHENIA GRAVIS APPEARING AFTER THYMECTOMY 
HERALDING RECURRENT THYMOMA
Paul Beckers1, Rudolf Mercelis2, Stijn Heyman1, Jeroen Hendriks1, 
Patrick Lauwers1, Paul Van Schil1  
1Antwerp University Hospital, Thoracic And Vascular Surgery, Ede-
gem/BELGIUM, 2Antwerp University Hospital, Neurology, Edegem/
BELGIUM
Thymoma is an uncommon neoplasm of the anterior mediastinum 
with a strong association with myasthenia gravis (MG). 30-50% of 
thymoma patients have MG. In 1.5-28% of cases MG first appears 
after removal of a thymoma. We present a case of a 72-year-old 
female Caucasian patient who presented with new onset of MG 
6 months after a two-stage resection of a B2 thymoma (stage III 
according to Masaoka-Koga) which was detected during investiga-
tion for autoimmune hemolytic anemia. MG was associated with a 
local intrapericardial recurrence of the tumor which was resected 
by median sternotomy. No adjuvant therapy was given. Literature 
research showed two previous cases of recurrent thymoma associ-
ated with new onset of MG. Both patients had metastatic disease, 
one in the lung, the other in the liver while our patient had a locally 
recurrent thymoma. New onset MG after thymectomy may be 
the first clinical sign of local recurrent or metastatic disease and 
should be extensively investigated. If feasible, repeat resection is 
the treatment of choice.
Disclosure: No significant relationships.
Keywords: Thymectomy, Recurrent Thymoma, Myasthenia gravis
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P63 EXPRESSION IN SUBTYPES OF THYMIC EPITHELIAL 
TUMOURS AND SIGNIFICANCE IN DIFFERENTIAL DIAGNOSIS
Gang Chen1, Hui Yu2, Yeqi Sun2, Jie Wu2, Liping Zhang2  
1Zhongshan Hospital, Fudan University, Pathology, Shanghai/
CHINA, 2Shanghai Pulmonary Hospital,Tongji University, Pathology, 
Shanghai/CHINA
Background: World Health Organization (WHO) classification 
of a thymoma was universally accepted in clinical diagnosis and 
closely related with prognosis of patients. Due to various reasons, 
pathologists often had trouble with exact classification, and lack-
ing available markers to solve this problem. P63 was found to be 
expressed in epithelial cells of various tumors, including thymic 
epithelial tumours. However, detailed research between the expres-
sion of P63 and thymomas was finite. Methods: The expression of 
P63 was examined in 134 cases of thymomas and thymic carci-
nomas by Immunohistochemistry (IHC), and the results were com-
pared with the initial and reviewed diagnoses of all the subjects. 
Results: Immunoreactivity for this marker was seen in 126 cases, 
with a distinctive pattern in each subtype and the results referring 
to P63 were consistent with the reviewed diagnoses. In addition, 
easily misdiagnosed subtypes were also indicated in the present 
study with the growth pattern showed by P63 expression. 
Conclusion: In view of the validity of P63, which was expressed 
in all the types of TET and showed a good and clear tumour cells 
number and distribution, in discerning subtypes of thymomas, P63 
was recommended as a regular marker for thymomas.
Disclosure: No significant relationships.
Keyword: Thymoma, IHC, p63, WHO Classification
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